MOOK　肺癌の臨床　2007-2008

出版社： 篠原出版新社
著者：
発行日： 2007-03-30
分野： 臨床医学：一般  >  癌/腫瘍一般
ISBN： 9784884126162
電子書籍版： 2007-03-30 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

8,800 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

4,400 円(税込)

購入する

商品紹介

現在、そして今後の肺癌診療につながる集学的内容にそった編集方針のもと、この一冊で最新の肺癌治療を展望することが出来る内容をめざし、季刊『肺癌の臨床』からの編集委員が気鋭の執筆者を厳選して構成。肺癌治療に携わるすべての医療関係者に読んでいただきたい、価値ある一冊。

目次

  • MOOK　肺癌の臨床　2007-2008

    ―目次―

    ◆疫　学◆
    　肺癌の年次動向と展望
    　肺癌は遺伝するか?：日本のコホート研究からのエビデンス
    　女性の肺癌

    ◆病理・分子生物学◆
    　肺腺癌研究の進歩
    　EGFR変異の高感度検出法
    　肺癌遺伝子変異の特性
    　肺神経内分泌性腫瘍の診断と組織発生
    　アスベスト曝露による肺癌･

    ◆発見・診断◆
    　前がん病変の早期診断（分子生物学的側面も加味して）
    　肺野末梢の早期肺癌をどう定義するか
    　日常診療（他疾患経過観察中）における胸部検診･
    　CT検診の妥当性と評価
    　PET検診は是か否か･
    　極細径気管支鏡･
    　気管支鏡下マイクロサンプリング法による気道上皮被覆液の
    　　解析−腫瘍マーカー解析とプロテオミクス−
    　肺門・縦隔病変に対する超音波気管支鏡下生検法･
    　肺癌を合併しやすい呼吸器疾患･
    　マススペクトロメトリーによる血清タンパク質解析

    ◆治　療（小細胞肺癌）◆
    　小細胞肺癌の化学療法の現状と課題
    　限局型小細胞肺癌の化学放射線療法の最近の動向
    　進展型小細胞癌の臨床試験・治療戦略･
    　小細胞癌に対するDose Intensive Chemotherapy
    　高齢者小細胞癌の治療
    　再発小細胞肺癌の治療戦略

    ◆治　療（非小細胞肺癌）◆
    　肺癌に対する胸腔鏡手術
    　I期肺癌に対する体幹部定位照射−重粒子線，陽子線を含む−
    　EGFR-TKIの現状：基礎−EGFRの感受性を決定する因子update･
    　EGFR−TKIの現状：臨床
    　VEGFターゲットの治療･
    　肺線維症を合併する肺癌に対する治療方針
    　非小細胞肺癌の新しい化学療法−TS-1，アリムタ−
    　切除不能III期非小細胞癌の新しい治療法･

    ◆診断・治療（中皮腫，胸膜，縦隔腫瘍）◆
    　胸膜中皮腫の年次動向と展望
    　中皮腫を早期発見をするために何をすべきか
    　胸膜中皮腫の免疫組織化学的染色による確定診断･
    　中皮腫の血液診断マーカー･
    　中皮腫の遺伝子異常−マイクロアレイを用いた網羅的解析
    　悪性胸膜中皮腫に対する外科手術成績からみた治療戦略･
    　悪性胸膜中皮腫に対する放射線治療の現状
    　悪性胸膜中皮腫の治療：手術の適応と実践
    　悪性胸膜中皮腫の治療−内科的治療の進歩−
    　胸腺腫・胸腺癌における内科的治療の動向･
    　胸膜・胸壁腫瘍の画像診断･
    　胸腺上皮性腫瘍の外科治療成績
    　縦隔胚細胞腫瘍に対する化学療法

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

疫学

P.8 掲載の参考文献
1) Marugame T, Kamo K, Sobue T, et al : Trends in smoking by birth cohorts born between 1900 and 1977 in Japan. Prev. Med 42 : 120-127, 2006
PubMed
2) Marugame T, Kamo K, Katanoda K, et al : Cancer incidence and incidence rates in Japan in 2000 : estimates based on data from 11 population-based cancer registries. Jpn J Clin Oncol 36 : 668-675, 2006
PubMed
3) Kaneko S, Ishikawa KB, Yoshimi I, et al : Projection of lung cancer mortality in Japan. Cancer Sci 94 : 919-923, 2003
PubMed
4) 大島明, 黒石哲生, 田島和雄 : がん・統計白書-罹患/死亡/予後-2004. 篠原出版新社, 東京, 2004
 
P.12 掲載の参考文献
1) Ferlay JBF, Pisani P, Parkin DM : GLOBOCAN 2002 : Cancer Incidence, Mortality and Prevalence Worldwide IARC Cancer Base No. 5. version 2.0, IARCPress. p. Lyon, 2004 http://www-dep.iarc.fr/GLOBOCAN 2002 database.
 
2) Doll R, Peto R : The causes of cancer : quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 66 (6) : 1191-1308, 1981
PubMed
3) IARC monographs on the evaluation of carcinogenic risks to humans : tobacoo smoke and involuntary smoking. LARC Monogr Eval Carcin og Risks Human Suppl 83 : 1-1452, 2004
 
4) Koop CE, Luoto J : "The Health Consequences of Smoking : Cancer," overview of a report of the Surgeon General. Public Health Rep 97 (4) : 318-324, 1982
PubMed
5) Sobue T, et al : Case-control study for lung cancer and cigarette smoking in Osaka, Japan : comparison with the results from Western Europe. Jpn J Cancer Res 85 (5) : 464-473, 1994
PubMed
6) Stanley KE : Lung cancer and tobacco-a global problem. Cancer Detect Prev 9 (1-2) : 83-89, 1986
 
7) Ahlbom A, et al : Cancer in twins : genetic and nongenetic familial risk factors. J Natl Cancer Inst 89 (4) : 287-293, 1997
PubMed
8) Tokuhata GK, Lilienfeld AM : Familial aggregation of lung cancer in humans. J Natl Cancer Inst 30 : 289-312, 1963
PubMed
9) McDuffie HH : Clustering of cancer in families of patients with primary lung cancer. J Clin Epidemiol 44 (1) : 69-76, 1991
PubMed
10) Ambrosone CB, et al : Lung cancer histologic types and family history of cancer. Analysis of histologic subtypes of 872 patients with primary lung cancer. Cancer 72 (4) : 1192-1198, 1993
PubMed
11) Hemminki K, et al : Genetic epidemiology of cancer : from families to heritable genes. Int J Cancer 111 (6) : 944-950, 2004
PubMed
12) Gauderman WJ, Morrison JL : Evidence for age-spechic genetic relative risks in lung cancer. Am J Epidemiol 151 (1) : 41-49, 2000
PubMed
13) Schwartz AG, Yang P, Swanson GM : Familial risk of lung cancer among nonsmokers and their relatives. Am J Epidemiol 144 (6) : 554-562, 1996
PubMed
14) Matakidou A, Eisen T, Houlston RS : Systematic review of the relationship between family history and lung cancer risk. Br J Cancer 93 (7) : 825-833, 2005
PubMed
15) Nitadori J, et al : Association between lung cancer incidence and family history of lung cancer : data from a large-scale population-based cohort study, the JPHC study. Chest 130 (4) : 968-975, 2006
PubMed
16) Matakidou A et al : Case-control study of famihal lung cancer risks in UK women. In t J Cancer 116 (3) : 445-450, 2005
 
17) Lubin JH, Blot WJ : Assessment of lung cancer risk factors by histologic category. J Natl Cancer Inst 73 (2) : 383-389, 1984
PubMed
18) McDuffie HH, Klaassen DJ, Dosman JA : Female-male differences in patients with primary lung cancer. Cancer 59 (10) : 1825-1830, 1987
PubMed
19) Zang EA, Wynder EL : Cumulative tar exposure. A new index for estimating lung cancer risk among cigarette smokers. Cancer 70 (1) : 69-76, 1992
PubMed
20) Risch HA, et al : Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. Am J Epidemiol 138 (5) : 281-293, 1993
PubMed
21) Dwyer T, et al : Higher lung cancer rates in young women than young men : Tasmania, 1983 to 1992. Cancer Causes Control 5 (4) : 351-358, 1994
PubMed
22) Zang EA, Wynder EL : Differences in lung cancer risk between men and women : examination of the evidence. J Natl Cancer Inst 88 (3-4) : 183-192, 1996
 
23) Thun MJ, et al : Excess mortality among cigarette smokers : changes in a 20-year interval. Am J Public Health 85 (9) : 1223-1230, 1995
 
24) Bach PB, et al : Variations in lung cancer risk among smokers. J Na tl Cancer Inst 95 (6) : 470-478, 2003
 
25) Bain C, et al : Lung cancer rates in men and women with comparable histories of smoldng. J Natl Cancer Inst 96 (11) : 826-834, 2004
PubMed
26) Hemminki K, Li X : Gender effects in familial cancer. Int J Cancer 1 02 (2) : 184-187, 2002
 
27) Sobue T, et al : Cigarette smoking and subsequent risk of lung cancer by histologic type in middle-aged Japanese men and women : the JPHC study. Int J Cancer 99 (2) : 245-251, 2002
PubMed
28) Liu Y, et al : Reproductive factors, hormone use and the risk of lung cancer among middle-aged never-smoking Japanese women : a large-scale population-based cohort study. Int J Cancer 117 (4) : 662-666, 2005
PubMed
29) Cote ML, et al : Risk of lung cancer among white and black relatives of individuals with early-onset lung cancer. JAMA 293 (24) : 3036-3042, 2005
PubMed
30) Salber EJ, Macmahon B : Cigarette smoking among high school students related to social class and parental smoking habits. Am J Public Health 51 : 1780-1789, 1961
 
31) Comings DE, et al : The dopamine D2 receptor (DRD2) gene : a genetic risk factor in smoking. Pharmacogenetics 6 (1) : 73-79, 1996
PubMed
32) Shields PG, et al : Dopamine D4 receptors and the risk of cigarette smoking in African-Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 7 (6) : 453-458, 1998
PubMed
33) Fujieda M, et al : Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobaccorelated lung cancer risk in male Japanese smokers. Carcinogenesis 25 (12) : 2451-2458, 2004
PubMed
34) Kreuzer M, et al : Histologic types of lung carcinoma and age at onset. Cancer 85 (9) : 1958-1965, 1999
PubMed
35) Sellers TA, et al : Lung cancer histologic type and family history of cancer. Cancer 69 (1) : 8691, 1992
 
36) Bromen K, et al : Aggregation of lung cancer in families : results from a population-based case-control study in Germany. Am 」 Epidemiol 1 52 (6) : 497-505, 2000
 
37) Poole CA, et al : Influence of a family history of cancer within and across multiple sites on patterns of cancer mortality risk for women. Am J Epidemiol 149 (5) : 454-462, 1999
PubMed
38) Hemminki K, Vaittinen P : Familial cancers in a nationwide family cancer database : age distribution and prevalence. Eur J Cancer 35 (7) : 1109-1117, 1999
 
39) Li X, Hemminki K : Familial and second lung cancers : a nation-wide epidemiologic study from Sweden. Lung Cancer 39 (3) : 255-263, 2003
PubMed
P.17 掲載の参考文献
1) Risch HA, Howe GR, Jain M, et al : Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. Am J Epidemiol 138 (5) : 281-293, 1993
PubMed
2) Zang EA, Wynder EL : Differences in lung cancer risk between men and women : examination of the evidence. J Natl Cancer Inst 88 (3-4) : 183-192, 1996
 
3) International Early Lung Cancer Action Program Investigators Women's Susceptibility to Tobacco Carcinogens and Survival After Diagnosis of Lung Cancer. JAMA 296 : 180-184, 2006
PubMed
4) Ryberg D, Hewer A, Phillips DH, et al : Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res 54 (22) : 5801-5803, 1994
PubMed
5) Mollerup S, Ryberg D, Hewer A, et al : Sex differences in lung CYPIAI expression and DNA adduct levels among lung cancer patients. Cancer Res 59 (14) : 3317-3320, 1999
 
6) Dresler CM, Fratelli C, Babb J, et al : Gender differences in genetic susceptibility for lung cancer. Lung Cancer 30 (3) : 153-160, 2000
PubMed
7) Taioli E, Wynder EL : Re : Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst 86 (11) : 869-870 No abstract available, 1994
 
8) Stabile LP, Davis AL, Gubish CT, et al : Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 62 (7) : 2141-2150, 2002
PubMed
9) Ramalingam S, Pawlish K, Gadgeel S, et al : Lung cancer in young patients : analysis of a Surveillance, Epidemiology, and End Results database. J Clin Oncol 16 (2) : 651-657, 1998
PubMed
10) de Perrot M, Licker M, Bouchardy C, et al : Sex diiiferences in presentation, management, and prognosis of patients with non-small cell lung carcinoma. J Thorac Cardiovasc Surg 119 (1) : 21-26, 2000
PubMed
11) Alexiou C, Onyeaka CV, Beggs D, et al : Do women live longer following lung resection for carcinoma? Eur J Cardioth orac Surg 21 (2) : 319-325, 2002
 
12) Lynch TJ, Bell DW, Sordella R, et al : Activating mutations in the epidermal groWth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (21) : 2129-2139, Epub 2004 Apr 29, 2004
 

病理・分子生物学

P.25 掲載の参考文献
1) Friedrich G : Periphere Lungenkrebse auf dem Boden Pleuranaher Narben. Virchows Arch. Pathol. ANat., 304, 230, 1939
 
2) Suzuki A, Shimosato Y, Nishiaki Y, et al : X-ray features of small cell carcinoma and adenocarcinoma of the lung. Shindan to Chiryo 65 : 1424, 1977 (in Japanese)
 
3) Shimosato Y, Hashimoto T, Kodama T, et al : Prognostic implications of fibrotic focus (scar) in small peripheral lung cancers. Am J Surg Pathol 4 : 365, 1980
PubMed
4) Kimula Y : A histochemical and ultrastructural study of adenocarcinoma of the lung. Am J Surg Pathol 2 : 253, 1978
PubMed
5) Shimosato Y, Kodama T, Kameya T, et al : Morphogenesis of Lung cancer (Shimosato Y, Melamed, MR, Nettesheim P, eds), Boca Ratton, Florida. CRC Press : 65-89, 1982
 
6) Gemma A, Noguchi M, Hirohashi H, et al : Clinicopathologic and immunohistochemical characteristics of goblet cell type adenocarcinoma of the lung. Acta Pathol Jpn 41 : 737-743, 1991
 
7) Hirata H, Noguchi M, Shimostato Y, et al : Clinicopathologic and immunohistochemical characteristics of bronchial gland cell type adenocarcinoma of the lung. Am J Clin Pathol 93 : 20-25, 1990
 
8) Noguchi M, Shimosato Y : The develoment and progressin of adenocarcinoma of the lung. Lung Cancer V (Hansen H, ed), Kluwer Academic, Boston, 131-142, 1994
 
9) Nakayama H, Noguchi M, Tsuchiya R, et al : Clonal growth of atypical adenomatous hyperplasia of the lung : cytofluorometric analysis of nuclear DNA content. Mod Pathol 3 : 314-320, 1990
PubMed
10) Yokozaki M, Kodama T, Yokose T, et al : Differentiation of atypical adenomatous hyperplasia and adenocarcinoma of the lung by use of DNA ploidy and morphometric analysis. Mod Pathol 9 : 1156-1164, 1996
PubMed
11) Travis WD, Colby TD, Corrin B, et al : Histological typing of lung and pleural tumours. World Health Organization International Histological Classification of Tumours, 3rd edition, Springer, Berlin, 1999
 
12) Noguchi M, Morikawa A, Kawasaki M, et al : Small adenocarcinoma of the lung. Histologic characterization and prognosis. Cancer 75 : 2844-2852, 1995
 
13) Mitsudomi T, Hamajima N, Ogawa M, et al : Prognostic significance of p53 alterations in patients with non-small cell lung cancer : a meta-analysis. Clin Cancer Res 6 : 4055-4063, 2000
PubMed
14) Tsuchiya E, Furuta R, Wada N, et al : High K-ras mutation rates in goblet-cell-type adenocarcinomas of the lungs. J Cancer Res Clin Oncol 121 : 577-581, 1995
 
15) Tanaka R, Wang D, Morishita Y, et al : Loss of function of p16 gene and prognosis of pulmonary adenocarcinoma. Cancer 103 : 608-615, 2005
PubMed
16) Hayes DN, Monti S, Parmigiani G, et al : Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol 24 : 5079-5090, 2006
PubMed
17) Paez JG, Janne PA, Lee JC, et al : EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy. Science 304 : 1497-1500, 2004
PubMed
P.31 掲載の参考文献
1) Lynch TJ, Bell DW, Sordella R, et al : Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 : 2129-2139, 2004
PubMed
2) Paez JG, Janne PA, Lee JC, et al : EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy. Science 304 : 1497-1500, 2004
PubMed
3) Mitsudomi T, Kosaka T, Endoh H, et al : Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23 : 2513-2520, 2005
PubMed
4) Tokumo M, Toyooka S, Kiura K, et al : The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 3 : 1167-1173, 2005
PubMed
5) Shigematsu H, Lin L, Takahashi T, et al : Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 5 : 339-346, 2005
PubMed
6) Kosaka T, Yatabe Y, Endoh H, et al : Mutations of the epidermal growth factor receptor gene in lung cancer : biological and clinical implications. Cancer Res 64 : 8919-8923, 2004
PubMed
7) Pao W, Miller V, Zakowski M, et al : EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101 : 13306-13311, 2004
PubMed
8) Inoue A, Suzuki T, Fukuhara T, et al : Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24 : 3340-3346, 2006
PubMed
9) Kimura H, Kasahara K, Kawaishi M, et al : Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 12 : 3915-3921, 2006
PubMed
10) Kimura H, Fujiwara Y, Sone T, et al : High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci 97 : 642-648, 2006
PubMed
11) Whitcombe D, Theaker J, Guy SP, et al : Detection of PCR products using self-probing amplicons and fluorescence. Nat Biotechnol 8 : 804-807, 1999
PubMed
12) Newton CR, Graham A, Heptinstall LE, et al : Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic J Acids Res 7 : 2503-2516, 1989
 
13) Arao T, Fukumoto H, Takeda M, et al : Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res 24 : 9101-9104, 2004
PubMed
P.39 掲載の参考文献
1) Hanahan D, Weinberg RA : The hallmarks of cancer. Cell 100 (1) : 57-70, 2000
PubMed
2) Ji H, Li D, Chen L, et al : The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9 (6) : 485-495, 2006
 
3) Airoldi I, Di Carlo E, Cocco C, et al : Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy. Blood 106 (12) : 3846-3853, 2005
PubMed
4) Lynch TI, Bell DW, Sordella R, et al : Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. NEJM 350 (21) : 2129-2139, 2004
 
5) Paez JG, Janne PA, Lee JC, et al : EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy. Science 304 (5676) : 1497-1500, 2004
PubMed
6) Toyota M, Issa JP : CpG island methylator phenotypes in aging and cancer. Semin Cancer Biol 9 (5) : 349-357, 1999
PubMed
7) Marsit CJ, Houseman EA, Christensen BC, et al : Examination of a CpG island methylator phenotype and implications of methylation profiles in solid tumors. Cancer Research 66 (21) : 10621-10629, 2006
PubMed
8) Suzuki M, Shigematsu H, Iizasa T, et al : Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer. Cancer 106 (10) : 2200-2207, 2006
PubMed
9) Forgacs E, Zochbauer-Muller S, Olah E, Minna JD : Molecular genetic abnormalities in the pathogenesis of human lung cancer. Pathol Oncol Res 7 (1) : 6-13, 2001
PubMed
10) Fong KM, Sekido Y, Gazdar AF, Minna JD : Lung cancer. 9 : Molecular biology of lung cancer : clinical implications. Thorax 58 (10) : 892-900, 2003
PubMed
11) Duwe BV, Steman DH, Musani AI : Tumors of the mediastinum. Chest 128 (4) : 2893-2909, 2005
 
12) Suzuki M, Chen H, Shigematsu H, et al : Aberrant methylation : common in thymic carcinomas, rare in thymomas. 0ncol Rep 14 (6) : 1621-1624, 2005
PubMed
13) Suzuki M, Ando S, Iida T, Fujisawa T, Kimura H : Multimodality therapy and significance of serum CYFRA21-1 for thymic carcinoma. Oncol Rep 13 (6) : 1127-1131, 2005
PubMed
14) Suzuki M, Toyooka S, Shivapurkar N, et al : Aberrant methylation profile of human malignant mesotheliomas and its relationship to SV40 infection. Oncogeee 24 (7) : 1302-1308, 2005
PubMed
15) Aoe K, Hiraki A, Murakami T, et al : Infrequent existence of simian virus 40 large T antigen DNA in malignant mesothelioma in Japan. Cancer Science 97 (4) : 292-295, 2006
PubMed
16) Airoldi I, Cocco C, Di Carlo E, et al : Methylation of the IL-12Rbeta2 gene as novel tumor escape mechanism for pediatric B-acute lymphoblastic leukemia cells. Cancer Res 66 (8) : 3978-3980, 2006
PubMed
17) Tang X, Shigematsu H, Bekele BN, et al : EGFR tyrosine ldnase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Research 65 (17) : 7568-7572, 2005
 
P.46 掲載の参考文献
1) Travis WD, Colby TV, Corrin B, et al : World Health Organization international histological classification of tumours ; histological typing of lung and pleural tumours. Berlin : Springer, 1999
 
2) Travis WD, Brambilla E, Mueller-Hermelink HK, et al : (ed.) Pathology and genetics of tumours of the lung, pleura, thymus and heart. WHO classhication of tumours 7, LARC press, 2004
 
3) 日本肺癌学会. 『臨床・病理肺癌取扱い規約改訂第6版』, 金原出版, 2003
 
4) 石川雄一. 肺の神経内分泌腫瘍のスペクトラム-鑑別診断のために. 病理と臨床 21 : 507-511, 2003
Medical*Online
5) Kalhor N, Zander DS, Liu J : TTF-1 and p63 for distinguishing pulmonary small-cell carcinoma from poorly differentiated squamous cell carcinoma in previously pap-stained cytologic material. Mod Pathol 19 (8) : 1117-1123, 2006
 
6) Iyoda A, Hiroshima K Toyozaki T, et al : Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer 91 (11) : 1992-2000, 2001
PubMed
7) Kobayashi Y, Tokuchi Y, Hashimoto T, et al : Molecular markers for reinforcement of histological subclassification of neuroendocrine lung tumors. Cancer Sci 95 (4) : 334-341, 2004
PubMed
8) Hiroshima K, Iyoda A Shida T, et al : Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma : a morphological, immunohistochemical, and molecular analysis. Mod Pathol 19 (10) : 1358-1368, 2006 Epub Jul 7, 2006
 
9) Jones MH, Virtanen C, Honjoh D, et al : Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identhied by gene expression profiles. Lancet 363 (9411) : 775-781, 2004
PubMed
10) Stuml N, Rossi G, Lantuejoul S, et al : Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. Hum Pathol 33 : 175-182, 2002
 
11) Watkins DN, Berman DM, Burkholder SG, et al : Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 422 (6929) : 313-317, 2003
PubMed
12) Hiroshima K, Iyoda A, Shibuya K, et al : Prognostic significance of neuroendocrine differentiation in adenocarcinoma of the lung. Ann Thorac Surg 73 (6) : 1732-1735, 2002
PubMed
13) Bhattachaliee A, Richards WG, Staunton J, et al : Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98 (24) : 13790-13795, 2001
 
14) Ionescu DN, Treaba D, Gilks CB, et al : Nonsmall cell lung carcinoma with neuroendocrine differentiation-an entity of no clinical or prognostic signhicance. Am J Surg Pathol 31 (1) : 26-32, 2007
 
15) Iyoda A, Hiroshima K, Moriya Y, et al : Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. Ann Thorac Surg 82 (5) : 1802-1807, 2006
PubMed
P.55 掲載の参考文献
1) IARC : Biological Effects of Asbestos. Bogovski P, Gilson JC, Timbell V, Wagner JC eds. LARC SCi Publica tions No. 8, WHO, Geneva, 1-346, 1973
 
2) Kroczynska B, Cutrone R, Bocchetta M, et al : Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in casing mesothelioma in hamsters. Proc National Aca Sci 103 : 14128-14133, 2006
 
3) 財団法人厚生統計協会 人口動態 厚生の指標 臨時増刊. 国民衛生の動向, 46-47, 2006
 
4) Lynch KM, Smith WA : Pulomonary asbestos M-carcinoma of the lung in asbestos-silicosis. Am J Resp 46 : 86-106, 1935
 
5) Hammond EC, Selikoff IJ, Seidman H : Asbestos exposure, cigarette smoking and death rates. Ann New York Acad Sci 330 : 473-475, 1979
 
6) McDonald JC : Cancer risk due to asbestos and man-made fibers. Recent Results Cancer Res 120 : 122-133, 1990
PubMed
7) Morinaga K, Yokoyama K, Sakatani K, et al : (Hurych J. Lesage M, David A, eds.) Lung cancer mortality among the asbestosis by smoking habit. Proceeding of VIIIh international Conference on occupational lung disease. ILO, Geneva, 372-376, 1989
 
8) 森永謙二 : 石綿関連疾患の疫学. Mebio 23 : 12-20, 2006
Medical*Online
9) Hessel PA, Gamble JF and McDonald JC : Asbestos, asbestosis and lung cancer : acritical assessment of the epidemiological evidence. Thorax 60 : 433-436, 2006
 
10) Kishimoto T, Ohnishi K and Saito Y : Clinical study of asbestos-related lung cancer. Industrial Health 41 : 94100, 2003.
 
11) 神山宣彦 : (森永謙二編). 第2節 石綿小体. 改訂新版 職業性石綿曝露と石綿関連疾患 -基礎知識と労災補償-, 79-101, 2005
 
12) 岸槌健太郎 : ヒト肺内に沈着するアスベスト繊維の分析. -殊に肺癌, 悪性中皮腫発生との相関-. 広大医誌 43 : 279-296, 1995
 
13) 北川正信, 村井嘉寛 : 石綿関連疾患の病理. 病理と臨床 7 : 702-708, 1989
 
14) 立山義朗, 井内康輝, 米原修治ら : アスベスト曝露と肺癌の相関 -手術摘出肺を用いた病理学的検討-. 病理と臨床 11 : 967-973, 1993
 
15) Mollo F, Magnani C, Bo P, et al : The attribution of lung cancers to asbestos exposure. A pathologic study of 924 unselected cases. Am J Clin Pathol 117 : 90-95, 2002
PubMed
16) 加藤勝也 : 増補改訂版 アスベスト関連疾患日常診療ガイド アスベスト関連疾患を見逃さないために 独立行政法人労働者健康福祉機構編. 労働調査会 27-31, 2006
 
17) 坂谷暁夫, 武島幸男, 井内康輝ら : アスベスト曝露が証明された肺癌の1例. 広島医学 59 : 247-248, 2006
 
18) 石田啓, 武島幸男, 井内康輝ら : アスベスト肺に肺癌を合併した1例. 広島医学 55 : 645-646, 2002
 
19) Consensus report : Anbestos, asbestosis, and cancer : the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health 23 : 311-316, 1997
 
20) Marczynski B, Czuppon A, Marek W, et al : Increased incidence of DNA double-srand breaks and anti-ds DNA antibodies in blood of workers occupationally exposed to asbestos. Hum Exp Toxicol 13 : 3-9, 1994
 
21) Fatma N. Jain A Bahman Q : Frequency of sister chromatid exchange and chromosomal aberrations in asbestos cement workers. Br J Ind Med 48 : 103-105, 1991
 
22) Takeshima Y, Seyama T, William PB, et al : p53 Mutations in Lung Cancers from Non-Smoking Atomic-Bomb Survivors. Lan cet 342 : 1520-1521, 1993
 
23) Wang X, Chrustiani DC, Wiencke JK, et al : Mutations in the p53 gene in lung cancer are associated with cigarette smoking and asbestos exposure. Cancer Epiderol Biolomarker Prev 4 : 543-548, 1995
 
24) Nelson HM, Christiani DC, Wiencke JK et al : K-ras mutation and occupational asbestos exposire in lung adenocarcinoma : asbestos-related cancer without asbestosis. Cancer Res 54 : 4570-4573, 1999
 
25) Nelson HH, Wiencke JK, Gunn L, et al : Chromosome 3p14 alterations in lung cancer : evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos. Cancer Res 58 : 1804-1807, 1998
PubMed
26) Kraunz KS, Lemos M, Godleski JJ, et al : Homozygous deletion of p16 (INK4a) and tobacco carcinogen exposure in nonsmall cell lung cancer. Int J Cancer 118 : 1364-1369, 2006
PubMed
27) Mossman BT, Lounsbury KM, and Rddy SP : Oxidant and signaling by mitogen-activated protein kinases in lung epithelium. Am J Resp Cell and, Mol Biol 34 : 666669, 2006
 
28) Wang X, Samet JM and Ghio AI : Asbestos-induced activation of cell signaling pathways in human bronchial epithelial cells. Exp Luflg Res 32 : 229-243, 2006
PubMed
29) Nymark P, Wikman H, Ruosaari S, et al : Identification of specific gene copy number changes in asbestos-related lung cancer. Cancer Res 66 (11) : 5737-5743, 2006
PubMed

発見・診断

P.62 掲載の参考文献
1) Travis WD, Colby TD, Corrin B, et al : Histological typing of lung and pleural tumours. World Health Organization International Histological Classification of Tumours, 3rd edition, Springer, Berlin, 1999
 
2) Noguchi M, Shimosato Y : The development and progression of adenocarcinoma of the lung. In : Hasnen H, ed. Lung Cancer V, Kluwer Academic. Boston, pp 131-142, 1994
 
3) Minami Y, Matsuno Y, Iijima T, et al : Prognostication of small-sized primary pulmonary adenocarcinomas by histopathological and karyometric analysis. Lung Cancer 48 : 339-348, 2005
PubMed
4) 森永正二郎, 下里幸雄 : 気管支, 肺の微小癌. D, 肺末梢微小腺癌の病理. 病理と臨床 5 (臨増) : 74-80, 1987
 
5) Kodama T, Biyajima S, Shimosato Y, et al : Morphometric study of adenocarcinoma and hyperplastic epithelial lesions in the peripheral lung. Am J Clin Pathol 85 : 146-151, 1986
PubMed
6) Anami Y, Matsuno Y, Yamada T, et al : A case of double primary adenocarcinoma of the lung with multiple atypical adenomatous hyperplasia. Pathol. Int 48 : 634-640, 1998
 
7) Nakayama H, Noguchi M, Tsuchiya R, et al : Clonal growth of atypical adenomatous hyperplasia of the lung : Cytofluorometric analysis of nuclear DNA content. Mod Pathol 3 : 314-320, 1990
PubMed
8) Noguchi M, Morikawa A, Kawasaki M, et al : Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 75 : 2844-2852, 1995
PubMed
9) 野口雅之 : 肺腺癌の上皮内腫瘍と多段階発癌. 呼吸 17 : 224-229, 1998
 
10) Aoyagi Y, Yokose T, Minami Y, et al : Accumulation of loss of heterozygosity and multistep carcinogenesis in pulmonary adenocarcinoma. Cancer Research 61 : 7950-7954, 2001
PubMed
11) Shimada A, Kano J, Ishiyama T, et al : Establishment of an immortalized cell line from a precancerous lesion of lung adenocarcinoma, and genes highly expressed in the early stages of lung adenocarcinoma development. Cancer Sci 96 : 668-675, 2005
PubMed
P.69 掲載の参考文献
1) Suzuki K, Nagai K, Yoshida J, et al : Conventional clinicopathologic prognostic factors in surgically resected nonsmall cell lung carcinoma : A comparison of prognostic factors for each pathologic TNM stage based on multivariate analyses [In Process Citation]. Cancer 86 (10) : 1976-1984, 1999
 
2) Yokoo H, Suckow EE : Peripheral lung cancers arising in scars. Cancer 14 : 1205-1215, 1961
PubMed
3) Shimosato Y, Suzuki A, Hashimoto T, et al : Prognostic implications of fibrotic focus (scar) in small peripheral lung cancers. Am J Surg. Pathol 4 (4) : 365-373, 1980
PubMed
4) Eto T, Suzuki H, Honda A, Nagashima Y : The changes of the stromal elastotic framework in the growth of peripheral lung adenocarcinomas. Cancer 77 (4) : 646-656, 1996
PubMed
5) Kurokawa T, Matsuno Y, Noguchi M, Mizuno S, Shimosato Y : Surgically curable "early" adenocarcinoma in the periphery of the lung [see comments]. Am J Surg Pathol 18 (5) : 431-438, 1994
 
6) Noguchi M, Morikawa A, Kawasaki M, et al : Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 75 (12) : 2844-2852, 1995
PubMed
7) Takise A, Kodama T, Shimosato Y, Watanabe S, Suemasu K : Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 cm in diameter. Cancer 61 (10) : 2083-2088, 1988
PubMed
8) Yamashiro K, Yasuda S, Nagase A, Hirata T, Nojima T, Nagashima K : Prognostic significance of an interface pattern of central fibrosis and tumor cells in peripheral adenocarcinoma of the lung. Hum Pathol 26 (1) : 67-73, 1995
PubMed
9) Sakurai H, Maeshima A, Watanabe S, et al : Grade of stromal invasion in small adenocarcinoma of the lung : histopathological minimal invasion and prognosis. Am J Surg Pathol 28 (2) : 198-206, 2004
PubMed
10) Suzuki K, Yokose T, Yoshida J, et al : Prognostic significance of the size of central fibrosis in peripheral adenocarcinoma of the lung. Ann Thorac Surg 69 (3) : 893-897, 2000
PubMed
11) Jang HJ, Lee KS, Kwon OJ, Rhee CH, Shim YM, Han J : Bronchioloalveolar carcinoma : focal area of ground-glass attenuation at thin-section CT as an early sign. Radiology 199 (2) : 485-488, 1996
PubMed
12) Zwirewich CV, Vedal S, Miller RR, Muller NL : Solitary pulmonary nodule : high-resolution CT and radiologic-pathologic correlation. Radiology 179 (2) : 469-476, 1991
PubMed
13) Aoki T, Tomoda Y, Watanabe H, et al : Peripheral lung adenocarcinoma : correlation of thin-section CT findings with histologic prognostic factors and survival. Radiology 220 (3) : 803-809, 2001
PubMed
14) Kodama K, Higashiyama M, Yokouchi H, et al : Prognostic value of ground-glass opacity found in small lung adenocarcinoma on high-resolution CT scanning. Lung Cancer 33 (1) : 17-25, 2001
PubMed
15) Matsuguma H, Yokoi K, Anraku M, et al : Proportion of ground-glass opacity on high-resolution computed tomography in clinical T1 N0 M0 adenocarcinoma of the lung : A predictor of lymph node metastasis. J Thorac Cardiovasc Surg 124 (2) : 278-284, 2002
PubMed
16) Ohde Y, Nagai K, Yoshida J, et al : The proportion of consolidation to ground-glass opacity on high resolution CT is a good predictor for distinguishing the population of non-invasive peripheral adenocarcinoma. Lung Cancer 42 (3) : 303-310, 2003
PubMed
17) Okada M, Nishio W, Sakamoto T, Uchino K, Tsubota N : Discrepancy of computed tomographic image between lung and mediastinal windows as a prognostic implication in small lung adenocarcinoma. Ann Thorac Surg 76 (6) : 1828-1832, 2003
PubMed
18) Suzuki K, Asamura H, Kusumoto M, Kondo H, Tsuchiya R : "Early" peripheral lung cancer : prognostic significance of ground glass opacity on thin-section computed tomographic scan. Ann Thorac Surg 74 (5) : 1635-1639, 2002
PubMed
19) Takamochi K, Nagai K, Yoshida J, et al : Pathologic N0 status in pulmonary adenocarcinoma is predictable by combining serum carcinoembryonic antigen level and computed tomographic findings. J Thorac Cardiovasc Surg 122 (2) : 325-330, 2001
PubMed
20) Suzuki K, Koike T, Asamura H, et al : Radiologic-pathologic correlation in stage IA adenocarcinoma of the lung. In : Proceedings of ASCO, 2006 ; Chicago, 2006
 
P.77 掲載の参考文献
1) Doll R, Peto R : Mortality in relation to smoking : 20 years' observations on male British doctors. Br Med J 2 : 1525-1536, 1976
PubMed
2) Stellman S, Takezaki T, Wang L, et al : Smoking and lung cancer risk in American and Japanese men : an international case-control study. Cancer Epidemiol Biomarkers Prev 10 : 1193-1199, 2001
PubMed
3) Lubin J, Blot W, Berrino F, et al : Patterns of lung cancer risk according to type of cigarette smoked. In t J Cancer 33 : 569-576, 1984
 
4) Hanai A, Benn T, Fujimoto I, et al : Comparison of lung cancer incidence rates by histological type in high and low incidence countries, with reference to the limited role of smoking. Jpn/Cancer Res 79 : 445-452, 1988
 
5) Sobue T, Suzuki T, Fujimoto I, et al : Lung cancer risk among exsmokers. Jpn J Cancer Res 82 : 273-279, 1991
PubMed
6) Bromen K, Pohlabeln H, Jahn I, et al : Aggregation of lung cancer in families : results from a population-based casecontrol study in Germany. Am J, Epidemiol 152 : 497-505, 2000
PubMed
7) Hemminki K, Li X : Familial risk for lung cancer by histology and age of onset : evidence for recessive inheritance. Exp Lung Res 31 : 205-215, 2005
PubMed
8) Doll R : Mortality from lung cancer in asbestos workers. Br J Ind Med 12 : 81-86, 1955
PubMed
9) Henderson D, Rodelsperger K, Woitowitz H, et al : After Helsinki : a multidisciplinary review of the relationship between asbestos exposure and lung cancer, with emphasis on studies published during 1997-2004. Pathology 36 : 517-550, 2004
PubMed
10) 大塚義紀, 浮田英明, 正木芳孝・他 : 特発性間質性肺炎 (IIP) からの肺癌発症-prospective study-. 日胸疾会誌 29 : 560-565, 1991
 
11) 青山克彦, 星永進, 生方幹夫・他 : 特発性間質性肺炎の臨床-肺癌の合併とその対応. 日胸 62 : S114-S120, 2003
 
12) Vesterinen E, Pukkala E, Timonen T, et al : Cancer incidence among 78,000 asthmatic patients. Int J Epidemiol 22 : 976-982, 1993
PubMed
13) Mayne S, Buenconsejo J, Janerich D : Previous lung disease and risk of lung cancer among men and women nonsmokers. Am J Epidemiol 149 : 13-20, 1999
PubMed
14) 低線量CTによる肺癌検診のあり方に関する合同委員会 : 低線量CTによる肺癌検診の手引き. 金原出版, 東京, 89, 2004
 
15) The Early Lung Cancer Action Project (ELCAP) : Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 355 : 1763-1771, 2006
 
P.82 掲載の参考文献
1) Melamed MR, Flehinger BJ, Zaman MB, et al : Screening for early lung cancer : results of the Memorial Sloan-Kettering study in New York Chest 86 : 44-53, 1984
PubMed
2) Fontana R, Sanderson DR, Woolner LB, et al : Lung cancer screening : the Mayo program. J Occup Med 28 : 746-750, 1986
 
3) Nishii K, Ueoka H, Kiura K, et al : A case-control study of lung cancer screening in Okayama Prefecture, Japan. Lung Cancer 34 : 325-332, 2001
PubMed
4) Tsukada H, Kurita Y, Yokoyama A, et al : An evaluation of screening for lung cancer in Niigata Prefecture, Japan : A population-based case-control study. Br J Cancer 85 : 1236-1331, 2001
 
5) Nakayama T, Baba T, Suzuki T, et al : An evaluation of chest X-ray screening for lung cancer in gunma prefecture, Japan : a population-based case-control study. Eur J Cancer 38 : 1380-1387, 2002
PubMed
6) Sagawa M, Tsubono Y, Saito Y, et al : A case-control stUdy for evaluating the efficacy of mass screening program for lung cancer in Miyagi Prefecture, Japan. Cancer 92 : 588-594, 2001
 
7) Sobue T, Moriyama N, Kaneko M, et al : Screening for lung cancer with low-dose helical computed tomography : Antilung cancer association project. J Clin Oncol 20 : 911-920, 2002
PubMed
8) Sone S, Takashima S, Li F, et al : Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet 351 : 1242-1245, 1998
PubMed
9) Kaneko M, Eguchi K, Ohmatsu H, et al : Peripheral lung cancer : screening and detection with low-dose spiral CT versus radiography. Radiology 201 : 798-802, 1996
PubMed
10) Nawa T, Nakagawa T, Kusano S, et al : Lung cancer screening using low-dose spiral CT-results of baseline and oneyear follow-up studies. Chest 122 : 15-20, 2002
 
11) Henschke C, McCauley D, Yakelevitz D, et al : Early Lung Action Project : overall design and findings from baseline screening. Lancet 354 : 99-105, 1999
 
12) The International Early Lung cancer Action Program Investigators Survival of Patients with Stage I Lung Cancer Detected on CT Screening, NEJM 355 : 1763-1771, 2006
 
13) 厚生労働省科学研究費補助金 第3次対がん総合戦略研究事業 : 革新的な診断技術を用いたこれからの肺がん検診手法の確立に関する研究 (CT肺がん検診有効性コホート研究・喀疾細胞診有効性症例対照研究), 主任研究者鈴木隆一郎, 平成17年度総括・分担研究報告書
 
14) 低線量CTによる肺癌検診のあり方に関する合同委員会 : 低線量CTによる肺癌検診の手引き, 金原出版, 東京, 2004
 
15) 平成17年度がん研究助成金「がん検診の適切な方法とその評価法の確立に関する研究」班 (主任研究者祖父江友孝) http://canscreen.ncc.go.jp/index.html
 
16) 花井耕造 : 胸部CTスクリーナー制度の構築について. CT検診 13 : 8, 2006
 
17) 長尾啓一 : 低線量CTによる肺癌検診の資格認定の必要性. 日本胸部臨床 65 : S114-118, 2006
 
18) Suganuma N, Kusaka Y, Hiraga Y, et al : Asbestos-Related Pleural Abnormalities Detected by Chest X-Ray : Fair Agreement with Detection by Computed Tomography. J Occup Health 43 : 365-370, 2001
 
19) www.iaslc.org.
 
P.88 掲載の参考文献
1) Yasuda S, Ide M, Fujii H, et al : Application of positron emission tomography imaging to cancer screening. British J Cancer 83 : 1607-1611, 2000
 
2) 窪田和雄 : FDG-PETの原理と評価法. 画像診断 23 : 1118-1128, 2003
 
3) Higashi K, Ueda Y, Seki H, et al : Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 39 (6) : 1016-1020, 1998
PubMed
4) Stahl A, Ott K, Weber WA, et al : Correlation of FDG uptake in gastric carcinomas with endoscopic and histopathological fingings. J Nucl Med 42 : 78, 2001
 
5) Torizuka T, Tamald N, Inokuma T, et al : In Vivo assessment of glucose metabolism in hepatocellular carcinoma with FD G-PET. J Nucl Med 36 : 1811-1817, 1995
 
6) Miyakita H, Tokunaga M, Onda H, et al : Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose trasporter 1 (GLUT-1) expression in the cancer. Int J Urol 9 (1) : 15-18, 2002
 
7) 村野剛志 : 医療被曝におけるリスク・ベネフィット解析. 茨城県立医療大学修士論文, 茨城, 2004
 
8) 日本核医学会・臨床PET推進会議 : FDG-PETがん検診ガイドライン (2004). 核医学 41 : 1-21, 2004
Medical*Online
9) Kojima S, Hara A, Kosaka N, et al : Cancer screening using whole-body 18FDG-PET scan in healthy voluntary subjects. J Clin Onc ASCO Annual Meeting Proceedings, 2004
 
10) 陣之内正史 : FDG-PETマニュアル検査と読影のコツ. (陣之内正史・編), インナービジョン, 東京, 61-63, 2003
 
11) Sone S, Takashima S, Li F, et al : Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet 351 : 1242-1245, 1998
PubMed
12) Henschke CI, McClauley DI, Yankelevitz DF, et al : Early lung cancer project : overall design and findings from baseline screening. Lancet 354 : 99-105, 1999
PubMed
13) Sobue T, Moriyama N, Kaneko M, et al : Screening for lung cancer with low-dose helical computed tomography. J Clin Onc 20 : 911-920, 2002
 
14) 金子昌弘, 斉藤雄一, 宮坂善和・他 : 肺がん検診におけるFDG-PETの役割. 臨床放射線 49 : 873-879, 2004
 
15) Noguchi M, Morikawa A, Kawasaki M, et al : Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 75 : 2844-2852, 1955
 
16) Pastrino U, Bellomi M, Landoni C, et al : Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers : 2 years results. Lancet 336 (23) : 593-597, 2003
 
P.97 掲載の参考文献
1) 日本気管支学会 : 気管支鏡臨床医のためのテクニックと画像診断. 医学書院, 東京, 1-21, 1998
 
2) Tanaka M, Satoh M, Kawanami O, et al : A new bronchofiberscope for the study of diseases of very peripheral airways. Chest 85 : 590-594, 1984
 
3) Tanaka T, Kohda E, Satoh M, et al : Diagnosis of peripheral lung cancer using a new type of endoscope. Chest 97 : 1231-1234, 1990
 
4) 浅野文祐 : 極細径気管支鏡検査とVirtual Bronchoscopy. 気管支学 24 : 551-556, 2002
Medical*Online
5) 坂英雄 : 末梢小型陰影の診断-極細径気管支鏡による生検診断-. 気管支学 26 : 487-489, 2004
Medical*Online
6) 浅野文祐, 松野祥彦, 小牧千人・他 : 肺末梢小型病変に対する極細径気管支鏡を用いたCTガイド下の経気管支診断. 日呼吸会誌 40 : 11-16, 2002
 
7) Kikawada M, Ichinose Y, Miyamoto D, et al : Peripheral airway findings in chronic obstructive pulmonary disease using ultrathin bronchoscope. Eur, Respir J 15 : 105-108, 2000
PubMed
8) 新島眞文, 江渡秀紀 : 末梢空洞性病変の診断に対する極細径気管支鏡の有用性. 気管支学 24 : 302-308, 2002
Medical*Online
9) Oki M, Saka H, Sako C, et al : Cavitating Invasive Pulmonary Aspergillosis Visualized and Diagnosed by Ultrathin Bronchoscopy. Chest 129 : 475-479, 2006
PubMed
10) Schuurnans MM, Michaud GC, Diacon AH, et al : Use of an ultrathin bronchoscope in the assessment of central airway obstruction. Chest 124 : 735-739, 2003
PubMed
11) Hasegawa S, Hitomi S, Murakawa M, et al : Development of an ultrathin fiberscope with a built-in channel for bronchoscopy in infants. Chest 110 : 1543-1546, 1996
PubMed
12) 浅野文祐, 木村智樹, 進藤丈・他 : CTガイド下極細径気管支鏡検査の有用性-通常の経気管支生検で診断できなかった肺末梢病変に対する検討-. 気管支学 24 : 80-85, 2002
 
13) 浅野文祐, 足達広和, 佐藤寛之・他 : 極細径気管支鏡-肺末梢病変に対して-. 気管支学 26 : 694-696, 2004
Medical*Online
14) Yamamoto S, Ueno K, Imamura F, et al : Usefulness of ultrathin bronchoscopy in diagnosis of lung cancer. Lung Cancer 46 : 43-48, 2004
PubMed
15) Oki M, Saka H, Kitagawa C, et al : Visceral Pleural Perforation in Two Cases of Ultrathin Bronchoscopy. Chest 127 : 2271-2273, 2005
PubMed
16) Chechani V : Bronchoscopic diagnosis of solitary pulmonary nodules and lung masses in the absence of endobronchial-abnormality. Chest 109 : 620-625, 1996
PubMed
17) 陳俊雄, 矢野孝子, 阿久沢浩司・他 : 径2cm以下の肺野孤立性腫瘤陰影に対する気管支鏡検査の診断的意義. 日胸疾会誌 34 : 266269, 1996
 
18) 遠藤正浩, 高田佳木, 大林加代子・他 : 2cm以下の末梢小型肺癌に対する経気管支診断と病理診断に関する考察. 肺癌 39 : 821-827, 1999
 
19) 田中繁, 梶川茂久, 森瓦希・他 : 細径気管支鏡は患者の負担を軽減できるか? -通常径気管支鏡との比較-. 気管支学 (in press)
 
20) Asano F, Matsuno Y, Matsushita T, et al : Transbronchial diagnosis of a pulmonary peripheral small lesion using an ultrathin bronchoscope with virtual bronchoscopic navigation. J Bronchol 9 : 108-111, 2002
 
21) 浅野文祐, 松野祥彦, 竹市直子・他 : Virtual Bronchoscopy-極細径気管支鏡ナビゲーションとして-. 気管支学 24 : 433-438, 2002
 
22) Shinagawa N, Yamazaki K, Onodera Y, et al : CT-guided transbronchial biopsy using an ultrathin bronchoscope with virtual bronchoscopic navigation. Chest 125 : 1138-1143, 2004
PubMed
23) Asano F, Matsuno Y, Ibuka T, et al : A barium marking method using an ultrathin bronchoscope with virtual bronchoscopic navigation (A case report). Respirology 9 : 409-413, 2004
PubMed
24) Asano F, Shindoh J, Shigemitsu K, et al : Ultrathin bronchoscopic barium marking with virtual bronchoscopic navigation for fluoroscopy-assisted thoracoscopic surgery. Chest 126 : 1687-1693, 2004
PubMed
25) 浅野文祐 : 気管支内視鏡挿入支援システム. 肺癌 5 : 473, 2003
Medical*Online
26) 浅野文祐, 松野祥彦, 鱸稔隆・他 : Virtual Bronchoscopyによるナビゲーションシステムを用いた呼吸器内視鏡診療. 気管支学 27 : 588-591, 2005
 
27) Asano F, Matsuno Y, Shinagawa N, et al : A virtual bronchoscopic navigation system for pulmonary peripheral lesions. Chest 130 : 559-566, 2006
PubMed
28) 浅野文祐, 松野祥彦, 鱸稔隆・他 : Auto-Guidance System for Insertion Bronchoscope+Thin GS-EBUSによる肺野末梢病変へのアプローチ. 気管支学 28 : 153, 2006
 
P.104 掲載の参考文献
1) Steinberg KP, Mitchell DR, Maunder RJ, et al : Safety of bronchoalveolar lavage in patients with adult respiratory distress syndrome. Am Rev Respir Dis 148 : 556-561, 1993
PubMed
2) 石坂彰敏, 斉藤達也. 非侵襲的な肺内生化学情報の収集 : 気道上皮被覆液採取のための気管支鏡的マイクロサンプリングプローベ. 医工学治療 12 : 711-713, 2000
 
3) Ishizaka A, Watanabe M, Yamashita T, et al : New bronchoscopic microsample probe to measure the biochemical constituents in epithelial lining fluid of patients with acute respiratory distress syndrome. Crit Care Med 29 : 896-898, 2001
PubMed
4) Ishizaka A, Matsuda T, Albertine KH, et al : Elevation of KL-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in acute respiratory distress syndrome. Am J Physiol Lung Cell Mo1 Physiol 286 : L1088-1094, 2004
 
5) Yamazaki K, Ogura S, Ishizaka A, et al : Bronchoscopic microsampling method for measuring drug concentration in epithelial lining fluid. Am J Respir Crit Care Med 168 : 1304-1307, 2003
PubMed
6) Obara M, Satoh H, Ishikawa H, et al : Diagnostic procedures in obtaining pathological materials for pulmonary nodules due to primary lung cancer. Oncol Rep 5 : 1237-1239, 1998
PubMed
7) Seyfer AE, Walsh DS, Graeber GM, et al : Chest wall implantation of lung cancer after thin-needle aspiration biopsy. Ann Thorac Surg 48 : 284-286, 1989
PubMed
8) Voravud N, Shin DM, Dekmezian RH, et al : Implantation metastasis of carcinoma after percutaneous fine-needle aspiration biopsy.ohest 102 : 313-315, 1992
PubMed
9) Yoshikawa T, Yoshida J, Nishimura M, et al : Lung cancer implantation in the chest wall following percutaneous fine needle aspiration biopsy. Jpn J Clin Oncol 30 : 450-452, 2000
PubMed
10) 石坂彰敏, 渡辺真純. 気管支鏡下マイクロサンプリング法と肺癌診断. 綜合臨床 50 : 2242-2244. 2001
 
11) Watanabe M, Ishizaka A, Ikeda E, et al : Contribution of bronchoscopic microsampling in the supplemental diagnosis of small peripheral lung carcinoma. Ann Thorac Surg 76 : 1669-1673, 2003
 
12) Cremendes MJ, Menendez R, Pastor A, et al : Diagnostic values of cytokeratin fragment 19 (CYFRA 21-1) bronchoalveolar lavage fluid in lung cancer. Respir, Med 92 : 766-771, 1998
 
13) Kohno N, Akiyama M, Kyoizumi S, et al : Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol 18 : 203-216, 1988
PubMed
14) Wilkins MR, Pasquali C, Appel RD, Ou K, et al : From proteins to Proteomes : large scale protein identification by twodimensional electrophoresis and amino acid analysis. Bio technology 1 4 : 61-65, 1994
 
15) Wilkins MR, Sanchez JC, Williams KL, et al : Current challenges and future applications for protein maps and posttranslational vector maps in proteome projects. Electrophoresis 17 : 830-833, 1996
PubMed
16) Bowler RP, Duda B, Chan ED, et al : Proteomic analysis of pulmonary edema fluid and plasma in patients with acute lung injury. Am J Physiol Lung Cell Mol Physiol 286 : 1095-1104, 2004
 
17) Bai Y, Galetskiy D, Damoc E, et al. High resolution mass spectrometric alveolar proteomics : identiiication of surfactant protein SP-A and SP-D modifications in proteinosis and cystic fibrosis patients. Proteomics 4 : 2300-2309, 2004
 
18) Fujii K, Nakano T, Kanazawa M, et al : Clinical-scale high-throughput human plasma proteome analysis : lung adenocarcinoma. Pro teomics 5 : 1150-1159, 2005
 
19) Hirano T, Kato H. Present status of clinical proteomic analysis for the early detection and determination of therapeutic strategy in lung cancer. Ann Thorac Cardiovasc Surg 12 : 4-9, 2006
PubMed
20) Merchant M, Weinberger SR Recent advancements in surface-enhanced laser desorption/ionization-time of flightmass spectrometry. Electrophoresis 21 : 1164-1177, 2000
PubMed
21) Fung ET, Enderwick C. ProteinChip clinical proteomics : computational challenges and solutions. Biotechniques Suppl : 34-38, 40-41, 2002
 
P.111 掲載の参考文献
1) Yasufuku K, Chhajed PN, Sekine Y, et al : Endobronchial ultrasound using a new convex probe-Apreliminary study on surgically resected specimens. Oncol Rep 11 : 293-296, 2004
 
2) Yasufuku K, Chiyo M, Sekine Y, et al : Real-time Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration of Mediastinal and Hilar Lymph Nodes. Chest 126 : 122-128, 2004
PubMed
3) Yasufuku K, Chiyo M, Yamada Y, et al : Endobronchial ultrasound guided TBNA for the diagnosis of hilar and mediastinal lesions. The Journal of Japan Society of Respiratory Endoscopy 27 : 114-120, 2005
 
4) Yasufuku K, Nakajima T, Motoori K, et al : Comparison of endobronchial ultrasound, Positron emission tomography, and Computed tomography for lymph node staging of lung cancer. Chest 130 : 710-718, 2006
PubMed
P.117 掲載の参考文献
1) Coultas DB, et al : Occupational lung cancer. Clinicsin chest medicine 13 : 341-354, 1992
PubMed
2) World Cancer Research Fund, American Institute for Cancer Research et al : The American Institute for Cancer Research. Washington DC, 35-52, 1997
 
3) Spain DM : The association of terminal bronchiolar carcinoma with chronic interstitial inflammation and fibrosis of the lungs. Am Rev Tuberc 76 (4) : 559-566, 1957
PubMed
4) Turner-Warwick M, Lebowitz M, Burrows B, et al : Cryptogenic fibrosing alveolitis and lung cancer. Thorax 35 (7) : 496-499, 1980
PubMed
5) Matsushita H, Tanaka S, Saiki Y, et al : Lung cancer associated with usual interstitial pneumonia. Pathol Int 45 (12) : 925-932, 1995
PubMed
6) Hubbard R, Venn A, Lewis S, et al : Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 161 (1) : 58, 2000
PubMed
7) Samet JM : Does idiopathic pulmonary fibrosis increase lung cancer risk? Am J Resoirorit Care Med 161 (1) : 1-2, 2000
 
8) 大塚義紀, 浮田英明, 正木芳孝・他 : 特発性間質性肺炎 (IIP) からの肺癌発症-prospective study-. 日胸疾会誌 29 (5) : 560-565, 1991
 
9) 日本タバコ産業調査, 2002年
 
10) 嶋康晃 : 薬の知識 53 (10) : 254-263, 2002
 
11) http://www.med.or.jp/nichinews/n150420e.html
 
12) U. S. Department of Health and Human Services. The Health Consequences of Smoking : Nicotine Addiction. A Report of the Surgeon General, 1988. U. S. Department of Health and Human Services, Public Health Services, Center for Disease Control, Center for Health Promotion and Education Office on Smoking and Health. DHHS Publication No. (CDC) 88-8406, Washington DC, 1988
 
13) Aubry MC, Myers JL, Douglas WW, et al : Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis. Mayo Clin Proc 77 (8) : 763-770, 2002
PubMed
14) Mizushima Y, Kobayashi M : Clinical characteristics of synchronous multiple lung cancer associated with idiopathic pulmonary fibrosis. A review of Japanese cases. Chest 108 (5) : 1272-1277, 1995
PubMed
15) Ma Y, Seneviratne CK, Koss M : Idiopathic pulmonary fibrosis and malignancy. Curr Opin Pulm Med 7 (5) : 278-282, 2001
PubMed
16) Park J, Kim DS, Shim TS, et al : Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Resplr J 17 (6) : 1216-1219, 2001
 
17) Meyer EC, Liebow AA : RELATIONSHIP OF INTERSTITIAL PNEUMONIA HONEYCOMBING AND ATYPICAL EPITHELIAL PRO LIFERATION TO CANCER OFTHE LUNG. Cancer 18 : 322-351, 1965
 
18) Uematsu K, Yoshimura A, Gemma A, et al : Aberrations in the fragile histidine triad (FHIT) gene in idiopathic pulmonary fibrosis. Cancer Res 61 (23) : 8527-8533, 2001
PubMed
19) Sozzi G, Sard L, De Gregorio L, et al : Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res 57 (11) : 2121-2123, 1997
PubMed
20) 米山武志 : 肺がんのbed side epidemiology 6価クロム肺がん例の分析による発がん機序の考察. 日本胸部臨床 42 (12) : 997-1001, 1983
 
21) 肺がんを併発するじん肺の健康管理等に関する報告書. 肺がんを併発するじん肺の健康管理等に関する検討会, 2002
 
22) 岸本卓巳, 井内康輝 : 第II章 石綿関連疾患. 2肺がん (2) 診断. 産業保健ハンドブック石綿関連疾患-予防・診断・労災補償-, 財団法人産業医学振興財団. 52-60, 2004
 
P.123 掲載の参考文献
1) Schulz-Knappe P, Schrader M, Standker L, et al : Peptide bank generated by large-scale preparation of circulating human peptides. J Chromatogr A 776 (1) : 125-132, 1997
PubMed
2) Richter R, Schulz-Knappe P, Schrader M, et al : Composition of the peptide fraction in human blood plasma : database of circulating human peptides. J Chromatogr B Biomed Sci Appl 726 (1-2) : 25-35, 1999
 
3) Anderson NL, Anderson NG : The human plasma proteome : history, character, and diagnostic prospects. Mol Cell Proteomics 1 (11) : 845-867, 2002
PubMed
4) Adkins JN, Varnum SM, Auberry KJ, et al : Toward a human blood serum proteome : analysis by multidimensional separation coupled with mass spectrometry. Mol Cell Proteomics 1 (12) : 947-955, 2002
 
5) Petricoin EF, Ardekani AM, Hitt BA, et al : Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 (9306) : 572-577, 2002
PubMed
6) Kozak KR, Amneus MW, Pusey SM, et al : Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips : potential use in diagnosis and prognosis. Proc Natl Acad Sci USA 100 (21) : 12343-12348, 2003
PubMed
7) Xiao Z, Luke BT, Izmirlian G, et al : Serum proteomic profiles suggest celecoxib-modulated targets and response predictors. Cancer Res 64 (8) : 2904-2909, 2004
PubMed
8) Petricoin EF, 3rd, Omstein DK, Paweletz CP, et al : Serum proteomic pattems for detection of prostate cancer. J Natl Cancer INst 94 (20) : 1576-1578, 2002
 
9) Adam BL, Qu Y, Davis JW, et al : Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62 (13) : 3609-3614, 2002
PubMed
10) Qu Y, Adam BL, Yasui Y, et al : Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 48 (10) : 1835-1843, 2002
PubMed
11) Banez LL, Prasanna P, Sun L, et al : Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol 170 (2 Pt 1) : 442-446 2003
 
12) Lehrer S, Roboz J, Ding H, et al : Putative protein markers in the sera of men with prostatic neoplasms. BJU Int 92 (3) : 223-225, 2003
PubMed
13) Lynch TJ, Bell DW, Sordella R, et al : Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (21) : 2129-2139, 2004
PubMed
14) Paez JG, Janne PA, Lee JC, et al : EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy. Science 304 (5676) : 1497-1500, 2004
PubMed
15) Pao W, Miller V, Zakowski M, et al : EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl. Acad Sci USA 101 (36) : 13306-13311, 2004
PubMed
16) Cappuzzo F, Hirsch FR, Rossi E, et al : Epidermal groWth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. JNatl Cancer Inst 97 (9) : 643-655, 2005
PubMed
17) Hirsch FR, Varella-Garcia M, Bunn PA Jr., et al : Molecular predictors of outcome with gefitinib in a phase III placebocontrolled study in advanced non-small-cell lung cancer. J Clin Oncol 24 (31) : 5034-5042, 2006
 
18) Hirsch FR, Varella-Garcia M, McCoy J, et al : Increased epidemal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes : a Southwest Oncology Group Study. J Clin Oncol 23 (28) : 6838-6845, 2005
 
19) Tsao MS, Sakurada A, Cutz JC, et al : Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 353 (2) : 133-144, 2005
PubMed
20) Taguchi F, Solomon B, Carbone DP, et al : Serum proteomic profiles for predicting response to gefitinib, a cross-laboratory technical validation study. AACR Meeting Abstracts Apr 2006 : 670, 2006
 
21) Solomon B, Gregorc V, Taguchi F, et al : Prediction of clinical outcome in non-small cell lung cancer (NSCLC) patients treated with gefitinib using Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) of serum. J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No 18S (June 20 Supplement), 7004, 2006
 
22) Perez EA, Suman VJ, Davidson NE, et al : HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24 (19) : 3032-3038, 2006
 

治療 ( 小細胞肺癌 )

P.134 掲載の参考文献
1) Hong WK, Nicaise C, Lawson R, et al : Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung : arandomized trial of the Bristol Lung Cancer Study Group. J Clin Oncol 7 : 450-456, 1989
 
2) Evans WK, Shepherd FA, Feld R, et al : VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 3 : 1471-1477, 1985
PubMed
3) Fukuoka M, Furuse K, Saijo N, et al : Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alernation of theses regimens in small-cell lung cancer. J Nathl Cancer Inst 83 : 855-861, 1991
 
4) Noda K, Nishiwaki Y, Kawahara M, et al : Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346 : 85-91, 2002
PubMed
5) Nasser H, Paul A, Corey L, et al : Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24 : 2038-2043, 2006
 
6) Cisplatin Combined With Either Irinotecan or Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer SWOG-SO124 (USA)
 
7) Ando Y, Saka H, Ando M, et al : Polymorphism of UDP-Glucuronosy transferase gene and irinotecan toxicity : a pharmacogenetic analysis. Cancer Research 60 : 6921-6929, 2000
 
8) A Phase III Study Comparing IP With EP Following EP/TRT for LD-SCLC JCOG0202 (Japan)
 
9) Okamoto H, Naoki K, Narita Y, et al : A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer. Lung Cacer 53 : 197-203, 2006
 
10) Sekine I, Takeda K, Nishiwaki Y, et al : Randomized phase II trial of irrinotecan plus cisplatin (IP) versus irinotecan, cisplatin plus etoposide (IPE) every three weeks in patients with extensive disease small cell lung cancer. ASCO7087, 2006
 
11) Yana T, Negoro S, Takada M, et al : Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer : West Japan Thoracic Oncology Group (WJTOG) study. In vest New Drugs Oct 13 : [Epub ahead of print], 2006
 
12) Ohe Y, Negoro S, Matsui K, et al : Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer. Ann Oncol 16 (3) : 430-436, 2005
PubMed
13) 高齢者の進展型小細胞肺癌に対する塩酸アムルビシンの製造販売後臨床試験 (第III相), 大日本住友製薬株式会社
 
14) 塚田裕子, 横山晶, 瀬戸貴司・他 : 既治療小細胞肺癌に対する塩酸アムルビシンの第II相試験, 第44回日本癌治療学会総会, 2006
 
15) Shibayama T, Hotta K, Takigawa N, et al : A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer. Lung Cancer 53 (2) : 189-195, 2006
PubMed
16) 尾下文浩, 斉藤春洋, 山田耕三・他 : 進展型小細胞肺癌に対する塩酸アムルビシンと塩酸イリノテカン併用療法の第I相試験, 第47回日本肺癌学会総会, 2006
 
17) Argiris A, Murren JR : Advances in chemotherapy for small cell lung cancer : single-agent activity of newer agents. Cancer J 7 (3) : 228-235, 2001
PubMed
18) Lilenbaum RC, Huber RM, Treat J, et al : Topotecan therapy in patients with relapsed small-cell lung cancer and poor performance statu s. Clin Lung Cancer Sep ; 8 (2) : 130-134, 2006
 
19) Seifar U, Fink T, Schade-Brittinge C, et al : Randomised phase II study comparing topotecan/carboplatin administration for 5 versus 3 days in the treatment of extensive-stage small-cell lung cancer. Ann Oncol Oct 27 : [Epub ahead of print], 2006
 
20) Reck M, Pawel J, Kaukel E, et al : Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin : quality of life and 6-years'-follow-up results from a randomised phase III trial. Lung Cancer 53 (1) : 67-75, 2006
 
21) Yamamoto N, Turutani J, Yashimura N, et al : Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. An ticancer Res 26 (1B) : 777-781, 2006
 
22) Scocinski MA, Weissman C, Hart LL, et al : Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Cin Oncol 20, 24 (30) : 4840-4847, 2006
 
23) Riedel RF, Crawford J, Dunphy F, et al : Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer. Lung Cancer Sep 25 : [Epub ahead of print], 2006
 
24) Carboplatin and Etoposide With or Without Thalidomide in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer. LLCG-STUDY12 (UK)
 
25) Roger S, Christian M, Andrew T, et al : Small cell lung cancer : state of the art and future perspectives. Lung Cancer 45 : 105-117, 2004
 
P.141 掲載の参考文献
1) Zelen M : Keynote address on biostatistics and data retrieval. Cancer Chemother Rep (Part 3) 4 : 31-42, 1973
 
2) Kemofsky D, Abelmann W, Craver L, et al : The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1 : 634, 1948
 
3) Miller AB, Fox W, Tall R, et al : Five-year follow-up of the Medical Research Council comparative trial of surgery and radiotherapy for the primary treatment of small-celled or oat-celled carcinoma of the bronchus. Lancet 2 (7169) : 501-505, 1969
PubMed
4) Green RA, Humphrey E, Close H, et al : Alkylating agents in bronchogenic carcinoma. Am J Med 46 : 516-525, 1969
PubMed
5) Bergsagel DE, Jenkin RD, Pringle JF, et al : Lung cancer : clinical trial of radiotherapy alone vs. radiotherapy plus cyclophosphamide. Cancer 30 : 621-627, 1972
PubMed
6) Roth BJ, Johnson DH, Einhom LH, et al : Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus altemation of these two regimens in extensive small-cell lung cancer : a phase III trial of the Southeastem Cancer study Group. J Clin Oncol 10 : 282-291, 1992
 
7) Fukuoka M, Furuse K, Saijo N, et al : Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus altemation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83 : 855-861, 1991
PubMed
8) Sundstrom S, Bremnes RM, Kaasa S, et al : Cisplatin and etoposide regimen is superior to cyclophosphamide, erirubicin, and vincristine regimen in small-cell lung cancer : results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 20 : 4665-4672, 2002
PubMed
9) Mascaux C, Paesmans M, Berghmans T, et al : A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung with methodology assessment and meta-analysis. Lung Cancer 30 : 23-36, 2000
PubMed
10) Chutte Jp, Chen T, Feigal E, et al : Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer : perceptible progress. J Clin Oncol 17 : 1794-1801, 1999
 
11) Turrisi AT, Kyungman K, Blum R, et al : Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340 (4) : 265-271, 1999
 
12) Choi NC, Hemdon JE 2nd, Rosenman J, et al : Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol 16 (11) : 3528-3536, 1998
 
13) Komaki R, Swann RS, Ettinger DS, et al : Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer : Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12. Int J Radiat Oncol Biol Phys 62 (2) : 342-350, 2005
PubMed
14) Kudoh S, Fujiwara Y, Takeda Y, et al : Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. J Clin Oncol 16 : 1068-1074, 1998
 
15) Noda K, Nishiwaki Y, Kawahara M, et al : Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346 (2) : 85-91, 2002
PubMed
16) Kubota K, Nishiwaki Y, Sugiura, et al : Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer : Japan Clinical Oncology Group 9903. Clin Cancer Res 11 (15) : 5534-5538, 2005
PubMed
17) Jeong HC, Lee SY, Kim JH, et al : Phase II study of irinotecan plus cisplatin with concurrent radiotherapy for the patients with limited-disease small-cell lung cancer. Lung Cancer 53 (3) : 361-366, 2006
 
18) Kato T, Nokihara H, Ohe Y, et al : Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC). JCO, 2006 ASCO Annual Meeting Proceeding Part I. Vol 24, No. 185, 2006
 
19) Onoda S, Masuda N, Seto T, et al : Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer : Thoracic Oncology Research Group Study 0301. J Clin Oncol 24 (34) : 5448-5453, 2006
PubMed
20) Shields TVV, Higgins GA Jr, Humphrey EW, et al : Surgical resection in the management of small cell carcinoma of the lung. J Thorac Cardiovasc Surg 84 (4) : 481-488, 1982
 
21) Tsuchiya R, Suzuki K, Ichinose Y, et al : Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-III a small cell lung cancer : the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101). J Thorac Cardiovasc Surg 129 (5) : 977-983, 2005
 
22) Lad T, Piantadosi S, Thomas P, et al : A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 106 (6 Suppl) : 320S-323S, 1994
 
23) Eberhardt W, Stamatis G, Stuschke M, et al : Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB : long-term results of a phase n trial. Br J Cancer 81 (7) : 1206-1212, 1999
 
24) Yamada K, Saijo N, Kojima A, et al : A Retrospective Analysis of Patients Receiving Surgery after Chemotherapy for Small Cell Lung Cancer. Jpn J of Clin Oncol 21 : 39-45, 1991
PubMed
25) Auperin A, Arriagada R, Pignon JP, et al : Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341 : 476-484, 1999
 
26) Pujol JL, Breton J, Gervais R, et al : A prospective randomized phase III, double-blind, placebo-controlled study of thalidomide in extensive-disease (ED) SCLC patients after response to chemotherapy (CT) : An intergroup study FNCLCC Cleo04-IFCT 00-01. JCO, 2006 ASCO proceeding 24, #7059
 
27) Giaccone G, Debruyne C, Felip E, et al : Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B ; Silva Study). J Clin Oncol 23 (28) : 6854-6864, 2005
PubMed
P.153 掲載の参考文献
1) Green RA, Humphrey E, Close H, et al : Alkylating agents in bronchogenic carcinoma. Am J Med 46 : 516-525, 1969
PubMed
2) Aisner J, Alberto P, Bitran J, et al : Role of chemotherapy in small cell lung cancer : A consensus report of the international association for the study of lung cancer workshop. Cancer Treat Rep 67 : 37-43, 1983
 
3) Einhom LH, Greco A, Wampler G, et al : Cytoxan, adriamycin, etoposide versus cytoxan, adriamycin, vincristine in the treatment of small cell lung cancer. Proc Am Soc Clin Oncol 6 : 168, 1987 (abstr)
 
4) Jett JR, Everson L, Themeau TM, et al : Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide : A randomized study of the North Central Cancer Treatment Group. J Clin Oncol 8 : 33-38, 1990
 
5) Jackson DV Jr, Case LD, Zekan PJ, et al : Improvement of long-term survival in extensive small cell lung cancer. J Clin Oncol 6 : 1161-1169, 1988
PubMed
6) Messeih AA, Schweitzer JM, Lipton A, et al : Addition of etoposide to cyclophosphamide, doxorubicine, and vincristine for remission induction and survival in patients with small cell lung cancer. Cancer Treat Rep 71 : 61-66, 1987
PubMed
7) Lowenbraun S, Birch R, Buchanan R, et al : Combination chemotherapy in small cell lung carcinoma : A randomized study of two intensive regimens. Cancer 54 : 2344-2350, 1984
PubMed
8) Schabel FM, Trader MW, Laster WK, et al : Cisdichlorodiamineplatinum (II) : Combination chemotherapy and crossresistance studies with tumors of mice. Cancer Treat Rep 63 : 1459-1473, 1979
 
9) Evans WK, Osoba D, Feld R, et al : Etoposide (VP-16) and cisplatin : An effective treatment for relapse of small-cell lung cancer. J Clin Onco13 : 65-71, 1985
 
10) Porter LL 3rd, Johnson DH, Hainsworth JD, et al : Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung. Cancer Treat Rep 69 : 479-481, 1985
PubMed
11) Einhorn LH, Crawford J, Birch R, et al : Cisplatin plus etoposide consolidation in following cyclophosphamide, doxorubicin, and vincristine in limited small cell lung cancer. J Clin Oncol 6 : 451-456, 1988
PubMed
12) Evans WK, Shepherd FA, Feld R, et al : VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 3 : 1471-1477, 1985
PubMed
13) Sierocki JS, Hilaris BS, Hopfan S, et al : Cisdichlorodiamineplatinum (II) and VP-16-213 : An active induction regimen for small cell carcinoma of the lung. Cancer Treat Rep 63 : 1593-1597, 1978
 
14) Fukuoka M, Furuse K, Saijo N, et al : Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus altemation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83 : 855-861, 1991
PubMed
15) Roth BJ, Johnson DH, Einhom LH, et al : Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer : a phase III trial of the southeastern cancer study group. J Clin Oncol 10 : 282-291, 1992
 
16) Pujol J-L, Carestia, and Daures J-P : Is there a case for ciaplatin in the treatment of small-cell lung cancer? A metaanalysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 83 : 8-15, 2000
 
17) Goldie JH, Coldman AJ and Gudauskas GA : Rationale for the use of altemating non-cross-resistant chemotherapy. Cancer Treat Rep 66 : 439-449, 1982
 
18) WK, Feld R, Murray N, et al : Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized trial by the National Cancer Institute of Canada. Ann Intern Med 107 : 451-458, 1987
 
19) Bunn PA, Curren M, Fukuoka M, et al : Chemotherapy in small cell lung cancer : a consensus report. Lung Cancer 5 : 127-134, 1989
 
20) Coldman AJ, Goldie JH : Impact of dose-intense chemotherapy on the developement of permanent drug resistance. Semin Oncol 14 (Suppl 4) : 29-33, 1987
 
21) Sculier JP, Paesmans M, Bureau G, et al : Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer : A phase III randomized study conducted by the European Lung Cancer Working Party. J Clin Oncol 11 : 1858-1865, 1993
 
22) Souhami RL, Rudd R, Ruiz de Elvira M-C, et al : Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer : A Cancer Research Campaign Trial. J Clin Oncol 12 : 1806-1813, 1994
 
23) Murray N, Shah A, Osoba D, et al : Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J Clin Oncol 9 : 1632-1638, 1991
PubMed
24) Fukuoka M, Masuda N, Negoro S, et al : CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Br J Cancer 75 : 306-309, 1997
PubMed
25) Furuse K, Fukuoka M, Nishiwaki Y, et al : Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-deisease small-cell lung cancer. J Clin Oncol 16 : 2126-2132, 1998
 
26) Murray N, Livingston RB, Shepherd FA et al : Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer : An intergroup study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 17 : 2300-2308, 1999
 
27) Spiro SG, Souhami RL, Geddes DM, et al : Duration of chemotherapy in small cell lung cancer : A Cancer Research Campaign trial. Br J Cancer 59 : 578-583, 1989
PubMed
28) Bleehan NM, Fayers PM, Girling DJ, et al : Controlled trial of twelve versus six courses of chemotherapy in the treatment of small cell lung cancer : Report to the Medical Research Council by its Lung Callcer Working Party. Br J Cancer 59 : 584-590, 1989
 
29) Bleehan NM, Girling DJ, Machin D, et al : A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or siX courses of etoposide and ifosfamide in small cell lung cancer (SCLC) : survival and prognostic factors. Br J Cancer 68 : 1150-1156, 1993
 
30) Giaccone G, Dalesio O, McVie GJ, et al : Maintenance chemotherapy in small-cell lung cancer : Long-term results of a randomized trial. J Clin Oncol 11 : 1230-1240, 1993
 
31) Beith JM, Clarke SJ, Woods RL, et al : Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung. Eur J Cancer 32A : 438-443, 1996
PubMed
32) Sculier JP, Paesmans M, Bureau G, et al : Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. J Clin Oncol 14 : 2337-2344, 1996
PubMed
33) Hanna NH, Sandler AB, Loehrer Sr PJ, et al : Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer : a Hoosier Oncology Group randomized study. Ann Oncol 13 : 95-102, 2002
 
34) Schiller JH, Adak S, Cella D, et al : Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer : E7593-Aphase Intrial of the Eastem Cooperative Oncology Group. J Clin Oncol 19 : 2114-2122, 2001
 
35) Mavroudis D, Papadakis E, Veslemes M, et al : A multicenter randomized clinical trial comparing paclitaxel-cisplatinetoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol 12 : 463-470, 2001
PubMed
36) Niell HB, Hemdon JE, Miller AA, et al : Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer : Cancer and Leukemia Group B Trial 9732. J Clin Oncol 23 : 3752-3759, 2005
 
37) Reck M, von Pawel J, Macha HN, et al : Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer. J Natl Cancer Inst 95 : 1118-1127, 2003
PubMed
38) Noda K, Nishiwaki Y, Kawahara M, et al : Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346 : 85-91, 2002
PubMed
39) Hanna N, Bunn Jr PA, Langer C, et al : Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage small-cell lung cancer. J Clin Oncol 24 : 2038-2043, 2006
PubMed
40) Eckardt JR, von pawel J, Papai Z, et al : Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus and etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol 24 : 2044-2051, 2006
PubMed
41) Kudoh S, Fujiwara Y, Takada Y, et al : Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. J Clin Oncol 16 : 1068-1074, 1998
PubMed
42) 住友製薬 : カルセド製品情報概要. 2002年12月作成版
 
43) Ohe Y, Negoro S, Matsui K, et al : Phase III study of amrubicin and cisplatin in previously untreated patients with extensive stage small cell lung cancer. Ann Oncol 16 : 430-436, 2005
PubMed
P.163 掲載の参考文献
1) Green JA, Dawson AA, Fell LF, et al : Measurement of drug dosage intensity in MVPP therapy in Hodgkin's disease. Br J Clin Pharmacol 9 (5) : 511-514, 1980
PubMed
2) Hryniuk W, Bush H : The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2 (11) : 1281-1288, 1984
PubMed
3) Hryniuk W : Important Advance in Oncology 1988 (Eds・DeVit Jr VT, Hellen S, Rosenberg SA), J. B. Lippincott Company, Philadelphia, 121-141, 1988
 
4) Tjan-Heijnen VC, Wagener DJ, Postmus PE An analysis of chemotherapy dose and dose-intensity in small-cell lung cancer : lessons to be drawn. Ann Oncol 13 (10) : 1519-1530, 2002
PubMed
5) Murray N, Shah A, Osoba D, et al : Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J Clin Oncol 9 (9) : 1632-1638, 1991
PubMed
6) Murray N, Livingston RB, Shepherd FA, et al : Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer : an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 17 (8) : 2300-2308, 1999
 
7) Furuse K, Fukuoka M, Nishiwaki Y, et al : Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group. J Clin Oncol 16 (6) : 2126-2132, 1998
 
8) Arriagada R, Le Chevalier T, Pignon JP, et al : Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 329 (25) : 1848-1852, 1993
PubMed
9) Leyvraz S, Pampallona S, Martinelli G, et al : Randomized phase III study of high-dose sequential chemotherapy (CT) supported by peripheral blood progenitor cells (PBPC) for the treatment of small cell lung cancer (SCLC) : Results of the EBMT Random-ICE trial. ASCO Annual Meeting Proceedings Part 1. Vol 24, No. 18S (June 20 Supplement) 7064, 2006
 
10) 木浦勝行, 原田実根 : 末梢血幹細胞移植の実際 (原田実根, 薗田精昭, 高上洋一・編), 南江堂, 東京, 166-170, 2001
 
11) Spitzer G, Farha P, Valdivieso M, et al : High-dose intensification therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma. J Clin Oncol 4 : 4, 1986
PubMed
12) Humblet Y, Symann M, Bosly A, et al : Late intenshication chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung : a randomized study. J Clin Oncol 5 : 1864, 1987
 
13) Elias AD, Ayash L, Frei E IIIrd, et al : Intensive combined modality therapy for limited-stage small-cell lung cancer. J Natl Cancer Inst 85 : 559, 1993
 
14) Elias AD, Ibrahim J, Skarin AT, et al : Dose-intensive therapy for limited-stage small-cell lung cancer : long-term outcome. J Clin Oncol 17 : 1175, 1999
 
15) Brugger W, Fetscher S, Hasse J, et al : Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancer. Semin Oncol 25 (Suppl 2) : 42, 1998
 
16) Bessho A, Ueoka H, Kiura K, et al : High-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood progenitor cell transplantation for small-cell lung cancer. Anticancer Res 19 : 693, 1999
 
17) Kiura K, Ueoka H, Tabata M, et al : Phase II study of high-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood stem cell transplantation for small-cell lung cancer Proc Am Soc Clin Oncol 22 (abstr 2540), 2003
 
18) Woll pJ, Hodgetts J, Lomax L, et al : Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 13 (3) : 652-659, 1995
PubMed
19) Fukuoka M, Masuda N, Negoro S, et al : CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Br J Cancer 75 (2) : 306-309, 1997
PubMed
20) Steward WP, von Pawel J, Gatzemeier U, et al : Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer : a prospective randomized study of 300 patients. J Clin Oncol 16 (2) : 642-650, 1998
PubMed
21) Thatcher N, Girling DJ, Hopwood P, et al : Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support : results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol 18 (2) : 395-404, 2000
 
22) Pettengell R, Woll PJ, Thatcher N, et al : Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood. J Clin Oncol 13 : 148-156, 1995
 
23) Lorigan P, Woll PJ, O'Brien ME, Ashcroft LF, et al : Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-ceU lung cancer. J Natl Cancer Inst 97 (9) : 666-674, 2005
 
24) Buchholz E, Drings P, Pilz L, Manegold C : Final results from a single centre, controlled study of standard versus dose intensified chemotherapy with sequential reinfusion of haemopoietic progenitor cells in SCLC. Proc Am Soc Clin Oncol 22 : 2572, 2003
 
25) Kiura K, Saijo N : Can dose-dense chemotherapy improve outcome in patients with better-prognosis small-cell lung cancer? Nat Clin Pract Oncol 2 (12) : 610-611, 2005
PubMed
26) Norton L : Conceptual and practical implications of breast tissue geometry : toward a more effective, less toxic therapy. Oncologist 10 (6) : 370-381, 2005
 
27) Gilewski T, Norton L : Holland-Frei Cancer 7 medicine (Eds・Kufe DW, Bast Jr RC, Hait WN, Hong WK Pollock RE, Weichselbaum RR, Holland JF, Frei III E) BC Decker Inc, London, 570-589, 2006
 
28) Frei III E, Eder J : Holland-Frei Cancer 7 medicine (Eds・Kufe DW, Bast Jr RC, Hait WN, Hong WK, Pollock RE, Weichselbaum RR, Holland JF, Frei III E) BC Decker Inc, London, 590-599, 2006
 
P.171 掲載の参考文献
1) Siu LL, Shepherd FA, Murray N, et al : Influence of age on the treatment of limited-stage small-cell lung cancer. J Clin Onco114 : 821-828, 1996
 
2) Yuen AR, Zou G, Turrisi AT, et al : Similar outcome of elderly patients in Intergroup trial 0096 : Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer 89 : 1953-1960, 2000
PubMed
3) Schild SE, Stella PJ, Brooks BJ, et al : Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly. Cancer 103 : 2349-2354, 2005
PubMed
4) Johnson DH : Small cell lung cancer in the elderly patient. Semin Oncol 24 : 484-491, 1997
PubMed
5) 西日本肺癌治療共同研究グループ : 高齢者小細胞肺癌はいかに治療すべきか? : 西日本肺癌治療共同研究グループにおけるアンケート調査. 癌と化学療法 26 : 797-804, 1999
 
6) Oshita F, Kurata T, Kasai T, et al : Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions. Jpn J Cancer Res 86 : 1198-1202, 1995
PubMed
7) Ardizzoni A, Favaretto A, Boni L, et al : Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer : Results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis-A Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study. J Clin Oncol 23 : 569-575, 2005
PubMed
8) Okamoto H, Watanabe K, Nishiwaki Y, et al : Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol 17 : 3540-3545, 1999
PubMed
9) Souhami RL, Spiro SG, Rudd RM, et al : Five-day oral etoposide treatment for advanced small-cellung cancer : Randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 89 : 577-580, 1997
PubMed
10) Westeel V, Murray N, Gelmon K, et al : New combination of the old drugs for elderly patients with small-cell lung cancer : A phase II study of the PAVE regimen. J Clin Oncol 16 : 1940-1947, 1998
PubMed
11) Okamoto H, Watanabe K, Kunikane H, et al : Randomized phase III trial of carboplatin plus etoposide vs. split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small cell lung cancer : JCOG9702. Proc Am Soc Clin Oncol 23 : Part II of II, late-breaking abstracts : 1094S (abstr 7010), 2005
PubMed
12) Takada M, Fukuoka M, Kawahara M, et al : Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer : results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 20 : 3054-3060, 2002
 
13) Murray N, Grafton C, Shah A, et al : Abbreviated treatment for elderly, infirm, or noncompliant patients with limitedstage small-cell lung cancer. J Clin Oncol 16 : 3323-3328, 1998
PubMed
14) Jeremic B, Shibamoto Y, Acimovic L, et al : Carboplatin, etoposide, and accelerated hyperfractionated radiotherapy for elderly patients With limited small cell lung carcinoma : a phase II study. Cancer 82 : 836-841, 1998
PubMed
15) Okamoto H, Naoki K, Narita Y, et al : A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer. Lung Cancer 53 : 197-203, 2006
PubMed
16) Pignon JP, Arriagada R, Ihde DC, et al : A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327 : 1618-1624, 1992
PubMed
17) Neubauer M, Schwartz J, Caracandas J, et al : Results of a phase II study of weekly paclitaxel plus carboplatin in patients with extensive small-cell lung cancer with Eastem Cooperative Oncology Group Performance Status of 2, or age > or=70 years. J Clin Oncol 22 : 1872-1877, 2004
 
18) Noda K, Nishiwaki Y, Kawahara M, et al : Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346 : 85-91, 2002
PubMed
19) Schmittel A, Fischer von Weikersthal L, Sebastian M, et al : A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small cell lung cancer. Ann Oncol 17 : 663-667, 2006
 
20) Timmer-Bonte JN, de Boo TM, Smit HJ, et al : Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer : A Dutch Randomized phase III study. J Clin Oncol 23 : 7974-7984, 2005
PubMed
21) Findlay MP, Griffin AM, Raghavan, et al : Retrospective review of chemotherapy for small cell lung cancer in the elderly : Dose the end justify the means? Eur J Cancer 27 : 1597-1601, 1991
PubMed
22) Radford JA, Ryder WD, Dodwell D, et al : Predicting septic complications of chemotherapy : An analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis. Eur J Cancer 29A : 81-86, 1992
PubMed
23) Smith TJ, Khatcheressian J, Lyman GH, et al : 2006 update of recommendations for the use of white blood cell growth factors : An evidence-based clinical practice guideline. J Clin Oncol 24 : 3187-3205, 2006
PubMed
24) Fujiwara K, Ueoka H, Kiura K et al : A phase I study of 3-day topotecan and cisplatin in elderly patients with small cell lung cancer. Cancer Chemoth er Pharmacol 57 : 755-760, 2006
 
P.178 掲載の参考文献
1) Seifter EJ, Ihde DC : Therapy of small cell lung cancer : a perspective on two decades of clinical research. Semin Oncol 15 : 278-299, 1988
PubMed
2) Glisson BS : Recurrent small cell lung cancer : update. Semin Oncol 30 : 72-78, 2003
PubMed
3) Batist G, Camey DN, Cowan KH, et al : Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer : clinical trial and in vitro correlates. J Clin Oncol 4 : 982-986, 1986
 
4) Johnson DH, Greco FA, Strupp J, et al : Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer : a phase II trial. J Clin Oncol 8 : 1613-1617, 1990
PubMed
5) Giaccone G, Donadio M, Bonardi G, et al : Teniposide in the treatment of small-cell lung cancer : the influence of prior chemotherapy. J Clin Oncol 6 : 1264-1270, 1988
PubMed
6) Ebi N, Kubota K, Nishiwaki Y, et al : Second-line chemotherapy for relapsed small cell lung cancer. Jpn J Clin Oncol 27 : 166-169, 1997
PubMed
7) Giaccone G, Ferrati P, Donadio M, et al : Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol 23 : 1697-1699, 1987
PubMed
8) Postmus PE, Berendsen HH, van Zandwijk N, et al : Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol 23 : 1409-1411, 1987
PubMed
9) Evans WK, Osoba D, Feld R, et al : Etoposide (VP-16) and cisplatin : an effective treatment for relapse in small-cell lung cancer. J Clin Oncol 3 : 65-71, 1985
PubMed
10) Porter LL, 3rd, Johnson DH, Hainsworth JD, et al : Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung. Cancer Treat Rep 69 : 479-481, 1985
PubMed
11) Einhorn LH, Pennington K, McClean J : Phase II trial of daily oral VP-16 in refractory small cell lung cancer : a Hoosier Oncology Group Study. Semin Oncol 17 : 32-35, 1990
 
12) Faylona EA, Loehrer PJ, Ansari R, et al : Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer : a Hoosier Oncology Group Trial. J Clin Oncol 13 : 1209-1214, 1995
 
13) Kubota K, Nishiwaki Y, Kakinuma R, et al : Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer. J Clin Oncol 15 : 292-296, 1997
PubMed
14) Takeda K, Negoro S, Sawa T, et al : A phase II study of topotecan in patients with relapsed small-cell lung cancer. Clin Lung Cancer 4 : 224-228, 2003
PubMed
15) Masuda N, Fukuoka M, Kusunoki Y, et al : CPT-11 : a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10 : 1225-1229, 1992
PubMed
16) Masuda N, Matsui K, Negoro S, et al : Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 16 : 3329-3334, 1998
 
17) Noda K, Nishiwaki Y, Kawahara M, et al : Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346 : 85-91, 2002
PubMed
18) Nakanishi Y, Takayama K, Takano K, et al : Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer. Am J Clin Oncol 22 : 399-402, 1999
PubMed
19) Onoda S, Masuda N, Seto T, et al : Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer : Thoracic Oncology Research Group Study 0301. J Clin Oncol 24 : 5448-5453, 2006
PubMed
20) Kato T, Nokihara H, Ohe Y, et al : Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC). J Clin Oncol (Meeting Abstracts) 24 : 7061, 2006
 
21) Smit EF, Fokkema E, Biesma B, et al : A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 77 : 347-351, 1998
PubMed
22) Groen HJ, Fokkema E, Biesma B, et al : Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide : a non-cross-resistant schedule. J Clin Oncol 17 : 927-932, 1999
PubMed
23) Domine M, Larriba J, Morales S, et al : Gemcitabine and Paclitaxel as Second Line Treatment in Small Cell Lung Cancer. A Multicentric Phase II Study. Proc Am Soc Clin Oncol 20 : 317a, 2001
 
24) Masters GA, Declerck L, Blanke C, et al : Phase II Trial of Gemcitabine in Refractory or Relapsed Small-Cell Lung Cancer : Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol 21 : 1550-1555, 2003
PubMed
25) Jassem J, Kamicka-Mlodkowska H, van Pottelsberghe C, et al : Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. Eur J Cancer 29A : 1720-1722, 1993
 
26) Smyth JF, Smith IE, Sessa C, et al : Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. Eur J Cancer 30A : 1058-1060, 1994
 
27) Sekine 1, Nishiwaki Y, Kakinuma R, et al : Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer : JCOG 9507. Br J Cancer 88 : 808-813, 2003
PubMed
28) Goto K, Sekine I, Nishiwaki Y, et al : Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer. Br J Cancer 91 : 659-665, 2004
PubMed
29) Kim Y, Goto K, Nishiwaki Y, et al : Phase II study of weekly cisplatin, etoposide and irinotecan (PE/CPT) for refractory relapsed small cell lung cancer (SCLC). J Clin Oncol (Meeting Abstracts) 24 : 7088, 2006
 
30) von Pawel J, Schiller JH, Shepherd FA, et al : Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17 : 658-667, 1999
PubMed
31) Eckardt JR, von Pawel J, Hainsworth JD, et al : Single agent oral topotecan (PO) versus intravenous topotecan (IV) in patients (pts) with chemosensitive small cell lung cancer (SCLC). An intemational phase III study. Proc Am Soc Clin Oncol 22 : 619, 2003
 
32) O'Brien ME, Ciuleanu TE, Tsekov H, et al : Phase III trial comparing supportive care alone With supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24 : 5441-5447, 2006
PubMed
33) Rocha Lima CM, Chiappori A : Treatment of relapsed small-cell lung cancer-a focus on the evolving role of topotecan. Lung Cancer 40 : 229-236, 2003
PubMed

治療 ( 非小細胞肺癌 )

P.184 掲載の参考文献
1) Japanese Association for Thoracic Surgery : Thoracic and cardiovascular surgery in Japan during 1999. Annual report by the Japanese Association for Thoracic Surgery. Jpn J Thorac Cardiovasc Surg 49 : 528-541, 2001
PubMed
2) Kazui T, Wada H, Fujita H : Thoracic and cardiovascular surgery in Japan during 2003. Annual report by the Japanese Association for Thoracic Surgery. Jpn J Thorac Cardiovasc Surg 53 : 517-536, 2005
PubMed
3) McKenna RJ Jr, Houck W, Fuller CB : Video-assisted thoracic surgery lobectomy : experience with 1,100 cases. Ann Thorac Surg 81 : 421-425, 2006
PubMed
4) Iwasaki M, Kaga K, Nishiumi N, et al : Experience with the two-windows method for mediastinal lymph node dissection in lung cancer. Ann Thorac Surg 65 : 800-802, 1998
PubMed
5) Park BJ, Flores RM, Rusch VW : Robotic assistance for video-assisted thoracic surgical lobectomy : technique and initial results. J Thorac Cardiovasc Surg 131 : 54-59, 2006
PubMed
6) Okada M, Sakamoto T, Yuki T, et al : Hybrid surgical approach of video-assisted minithoracotomy for lung cancer : significance of direct visualization on quality of surgery. Chest 128 : 2696-2701, 2005
PubMed
7) Craig SR, Leaver HA, Yap PL, et al : Acute phase response following minimal access and conventional thoracic surgery. Eur J Cardiothorac Surg 20 : 455-463, 2001
PubMed
8) Shigemura N, Akashi A, Nakagiri T, et al : Complete vs assisted thoracoscopic approach. A prospective randomized trial comparing a variety of video-assisted thoracoscopic lobectomy techniques. Surg Endosc 18 : 1492-1497, 2004
 
9) Ng CS, Wan S, Hui CW, et al : Video-assisted thoracic surgery lobectomy for lung cancer is associated with less immunochemokine disturbances than thoracotomy. Eur J Cardiothorac Surg 31 : 83-87, 2007
PubMed
10) Kirby TJ, Mack MJ, Landreneau RI, et al : Lobectomy-video-assisted thoracic surgery versus muscle-sparing thoracotomy. A randomized trial. J 7] horac Cardiovasc Surg 1109 : 997-1001, 1995
 
11) Giudicelli R, Thomas P, Lonjon T, et al : Video-assisred minithoracotomy versus muscle-sparing thoracotomy for performing lobectomy. Ann Thorac Surg 58 : 712-717, 1994
PubMed
12) Solaini L, Prusciano F, Bagioni P, et al : Video-assisted thoracic surgery major pulmonary resections. Present experience. Eur J Cardiovasc Surg 20 : 437-442, 2001
 
13) Nomori H, Horio H, Naruke T, et al : What is the advantage of a thoracoscopic lobectomy over a limited thoracotomy procedure for lung cancer surgery? Ann Thorac Surg 72 : 879-884, 2001
 
14) Swanson SJ, Herndon J, D'Amico A, et al : Results of CALGB 39802 : feasibility of video-assisted thoracic surgery (VATS) lobectomy for early stage lung cancer. J Clin Oncol 21 : A-1158, 2002
 
15) Raviaro G, Varoli F, Vergami C, et al : Long-term survival after videothoracoscopic lobectomy for stage I lung cancer. Chest 126 : 725-732, 2004
 
16) Sugi K, Kaneda Y, Esato K : Video-assisted thoracoscopic lobectomy achieves a satisfactory long-term prognosis in patients with clinical stage IA lung cancer. World J Surg 24 : 27-30, 2000
PubMed
17) Shigemura N, Akashi A, Funaki S, et al : Long-term outcomes after a variety of video-assisted thoracoscopic lobectomy approaches for clinical stage I A lung cancer : a multi-institutional study. J Thorac Cardiovasc Surg 132 : 507-512, 2006
 
18) Shiraishi T, Shirakusa T, Hiratsuka M, et al : Video-assisted thoracoscopic surgery lobectomy for c-T1N0M0 primary lung cancer : its impact on locoregional control. Ann Thorac Surg 82 : 1021-1026, 2006
PubMed
19) Goya T, Asamura H, Yoshimura H, et al : Prognosis of 6644 resected non-small cell lung cancers in Japan : a Japanese lung cancer registry study. Lung Cancer 50 : 227-234, 2005
PubMed
20) Watanabe A, Koyanagi T, Ohsawa H, et al : Systematic node dissection by VATS is not inferior to that through an open thoracotomy : a comparative clinicopathologic retrospective study. Surgery 138 : 510-517, 2005
PubMed
21) Sagawa M, Sato M, Sakurada A, et al : A prospective trial of systematic nodal dissection for lung cancer by videoassisted thoracic surgery : can it be perfect? Ann Thorac Surg 73 : 900-904, 2002
PubMed
P.193 掲載の参考文献
1) Blomgren H, Lax I, Goeranson H, et al : Radiosurgery for tumors in the body : Clinical experience using a new method. Journal of Radiosurgery 1 : 63-74, 1998
 
2) Uematsu M, Shioda A, Tahara K, et al : Focal, high dose, and fractionated modhied stereotactic radiation therapy for lung carcinoma patients. Callcer 82 : 1062-1070, 1998
PubMed
3) Lax I, Blomgren H, Larson D, et al : Extracranial stereotactic radiosurgery of localized target. Journal of Radiosurgery 1 : 135-148, 1998
 
4) Negoro Y, Nagata Y, Aoki T, et al : The effectiveness of an immobilization deVice in conformal radiotherapy for lung tumor : reduction of respiratory tumor movement and evaluation of daily set-up accuracy. Int J Radiat Oncol Biol Phys 50 : 889-898, 2001
 
5) Onishi H, Kuriyama K, Komiyama T, et al : A new irradiation system for lung cancer combining linear accelerator, computed tomography, patient self-breath-holding, and patient-directed breath-control without respiratory monitoring devices. IJROBP 56 : 14-20, 2003
 
6) Shirato H, Shimizu T, Shimizu S : Real-time tumor tracking radiotherapy. Lancet 353 : 1331-1332, 1999
PubMed
7) International Commission on Radiation Units and Measurements (ICRU) : Report 62, ICRU Publications, 1999
 
8) Nagata Y, Takayama K, Matsuo Y, et al : Clinical outcomes of a Phase I/II study of 48Gy of stereotactic body radiation therapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 63 : 5, 1427-1431, 2005
 
9) Uematsu M, Shioda A, et al : Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer : a 5-year experience. Int J Radiat Oncol Biol Phys 51 (3) : 666-670, 2001
 
10) Onimanl R, Shirato H, Shimizu S, et al : Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int J Radiat Oncol Biol Phys 56 : 126-136, 2003
 
11) Arimoto T, Usubuchi H, Matsuzawa T, et al : Small volume multiple non-coplanar arc radiotherapy for tumors of the lund, head & neck and the abdominopelvic region. CAR'98 Computer assisted radiology and surgery. edited by HU. Lemke, Elsevier, Tokyo, 1998
 
12) Onishi H, Araki T, Shirato H, et al : Stereotactic hypofractionated high-dopse irradiation for Stage I nonsmall cell lung carcinoma. Cancer 101 : 1623-1631, 2004
 
13) Wulf J, Haedinger U, Oppitz U, et al : Stereotactic radiotherapy for primary lung cancer and pulmonary metastases : A noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys 60 : 186-196, 2004
PubMed
14) Timmerman R, Papiez L, McGany R, et al : Extracranial stereotactic radioablation : Results of a phase I shldy in medically inoperable stage I non-small cell lung cancer. Chest 124 : 1946-1955, 2003
 
15) Timmemlan R, McGarry R, Yiannoutsos C, et al : Excesive toxicity when treating central tumors in a Phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. JCO 24 : 4833-4839, 2006
 
16) Shirato H, Shimizu S, Shimizu T, et al : Real-time tumor-tracking radiotherapy. Lancet 353 : 1331-1332, 1999
PubMed
17) Adler JR, et al : The Cyberknife : aframeless robotic system for radiosurgery. Stereotact Funct Neurosurg 69 : 124-128, 1997
PubMed
18) Tamaki N, et al : C-arm multi-axis rotation stereotactic linac radiosurgery system. J of Radiosurgery 3 : 21-27, 2000
 
19) Mackie TR, Holmes T, et al : Tomotherapy : A new concept for the delivery of dynamic conformal radiotherapy. Med Phys 20 : 1709-1716, 1993
PubMed
20) Kamino Y, Takayama K, Kokubo M, et al : Development of a four-dimensional Image-guided Radiotherapy system with a gimballed X-ray head. UROBP 66 : 271-278, 2006
 
21) Nihei K, Ogino T, Ishikura S, et al : High-dose proton beam therapy for stage I non-small-cell lung cancer. UROBP 65 : 107-111, 2006
 
P.200 掲載の参考文献
1) Paez JG, Janne PA, Lee JC, et al : EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy. Science 304 : 1497-1500, 2004
PubMed
2) Lynch TJ, Bell DW, Sordella R, et al : Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 : 2129-2139, 2004
PubMed
3) Hynes NE, Lane HA : ERBB receptors and cancer : the complexity of targeted inhibitors. Nat Rev Cancer 5 : 341-354, 2005
PubMed
4) Zhou BB, Peyton M, He B, et al : Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 10 : 39-50, 2006
PubMed
5) Kakiuchi S, Daigo Y, Ishikawa N, et al : Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet 13 : 3029-3043, 2004
PubMed
6) Ishikawa N, Daigo Y, Takano A, et al : Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res 65 : 9176-9184, 2005
PubMed
7) Tsao MS, Sakurada A, Cutz JC, et al : Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 353 : 133-144, 2005
PubMed
8) Mitsudomi T, Kosaka T, Yatabe Y : Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol 11 : 190-198, 2006
 
9) Matsuo K, Ito H, Yatabe Y, et al : Risk factors differ for non-small-cell lung cancers with and without EGFR mutation : assessment of smoking and sex by a case-control study in Japanese. Cancer Sci 2006
 
10) Eberhard DA, Johnson BE, Amler LC, et al : Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23 : 5900-5909, 2005
PubMed
11) Mitsudomi T, Kosaka T, Endoh H, et al : Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23 : 2513-2520, 2005
PubMed
12) Jackman DM, Yeap BY, Sequist LV, et al : Exon 19 deletion mutations of epidermal groWth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 12 : 3908-3914, 2006
PubMed
13) Greulich H, Chen T-H, Feng W, et al : Oncogenic transfomation by inhibitor-sensitive and resistant EGFR mutations. Plos Med 2 : e313, 2005
 
14) Han SW, Kim TY, Jeon YK, et al : 0ptimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal groWth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 12 : 2538-2544, 2006
PubMed
15) Kobayashi S, Boggon TJ, Dayaram T, et al : EGFR mutation and resistance of non-smal1-cell lung cancer to gefitinib. N Engl J Med 352 : 786-792, 2005
PubMed
16) Pao W, Miller VA, Politi KA, et al : Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain. PIOS, Med 2 : e73, 2005
PubMed
17) Toyooka S, Kiura K, and Mitsudomi T : EGFR mutation and response of lung cancer to gefitinib. N Engl J Med 352 : 2136 ; author reply 2136, 2005
PubMed
18) Cappuzzo F, Hirsch FR, Rossi E, et al : Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 97 : 643-655, 2005
PubMed
19) Hirsch FR, Varella-Garcia M, McCoy J, et al : Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes : a Southwest Oncology Group Study. J Clin Oncol 23 : 6838-6845, 2005
 
20) Takano T, Ohe Y, Sakamoto H, et al : Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clon Oncol 23 : 6829-6837, 2005
 
21) Cappuzzo F, Varella-Garcia M, Shigematsu H, et al : Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 23 : 5007-5018, 2005
PubMed
22) Hirata A Hosoi F, Miyagawa M, et al : HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.oancer Res 65 : 4253-4260, 2005
 
23) Cappuzzo F, Toschi L, Domenichini I, et al : HER3 genomic gain and sensitivity to gefitinib in advanced non-smallcell lung cancer patients. Br J Cancer 93 : 1334-1340, 2005
 
24) Shigematsu H, Takahashi T, Nomura M, et al : Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65 : 1642-1646, 2005
PubMed
25) Wang SE, Narasanna A, Perez-Torres M, et al : HER2 kinase domain mutation results in constitUtive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10 : 25-38, 2006
PubMed
26) Yarden Y, Sliwkowski MX : Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2 : 127-137, 2001
PubMed
27) Kosaka T, Yatabe Y, Endoh H, et al : Mutations of the epidermal growth factor receptor gene in lung cancer : biological and clinical implications. Cancer Res 64 : 8919-8923, 2004
PubMed
28) Pao W, Wang TY, Riely GJ, et al : KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib. PLoS, Med 2 : e17, 2005
PubMed
29) Endoh H, Yatabe Y, Kosaka T, et al : PTEN and PIK3A expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. J Thorac Oncol 1 : 629-634, 2006
 
30) Miller VA, Zakowski M, Riely GJ, et al : EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC) : Results of a prospective phase II trial. J Clin Oncol (Meeting Abstracts.) 24 : 7003, 2006
 
31) Sansal I, Sellers WR : The biology and clinical relevance of PTEN tumor suppressor pathway. J Clin Oncol 22 : 2954-2963, 2004
PubMed
32) Cappuzzo F, Magrini E, Ceresoli GL, et al : Akt phosphorylation and gefitinib efficacy in patients with advanced nonsmall-cell lung cancer. J Natl Cancer Inst 96 : 1133-1141, 2004
PubMed
P.210 掲載の参考文献
1) Nakagawa K, et al : Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 14 : 922-930, 2003
PubMed
2) Ranson M, et al : ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors : results of a phase I trial. J Clin Oncol 20 : 2240-2250, 2002
PubMed
3) Herbst RS, et al : Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD 1839 is generally welltolerated and has activity in non-small-cell lung cancer and other solid tumors : Results of a phase I trial. J Clin Oncol 20 : 3815-3825, 2002
PubMed
4) Baselga J, et al : Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD 1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20 : 4292-4302, 2002
PubMed
5) Fukuoka M, et al : A multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21 : 2237-2246, 2003
 
6) Kris MG, et al : Efficacy of gefitinib, an inhibitor of the epidemlal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer : a randomized trial. JAMA 290 : 2149-2158, 2003
PubMed
7) Miller VA, et al : Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22 : 1103-1109, 2004
PubMed
8) Takano T, et al : Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 45 : 93-104, 2004
PubMed
9) Ando M, Okamoto I, Yamamoto N, et al : Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 24 : 2549-2556, 2006
PubMed
10) Kim YH, Ishii G, Goto K, et al : Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung. Clin Cancer Res 10 : 7311-7317, 2004
PubMed
11) Lynch TJ, Bell DW, Sordella R, et al : Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 : 2129-2139, 2004
PubMed
12) Paez JG, Janne PA, Lee JC, et al : EGFR mutations in lung cancer : Correlation with clinical response to gefitinib therapy. Science 304 : 1497-1500, 2004
PubMed
13) Takano T, Ohe Y, Sakamoto H, et al : Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23 : 6829-6837, 2005
PubMed
14) Mitsudomi T, Kosaka T, Endoh H, et al : Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small cell lung cancer with postoperative recurrence. J Clin Oncol 23 : 2513-2520, 2005
PubMed
15) Han SW, Kim T-Y, Hwang PG, et al : Predictive and prognostic impact of epidemlal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23 : 2493-2501, 2005
PubMed
16) Pao W, Miller V, Zakowski M, et al : EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101 : 13306-13311, 2004
PubMed
17) Kosaka T, Yatabe Y, Endoh H, et al : Mutations of the epidermal growth factor receptor gene in lung cancer : biological and clinical implications. Cancer Res 64 : 8919-8923, 2004
PubMed
18) Huang SF, Liu HP, Li LH, et al : High frequency of epidermal groWth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10 : 8195-8203, 2004
PubMed
19) Shigematsu H, Lin L, Takahashi T, et al : Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97 : 339-346, 2005
PubMed
20) Marchetti A, Martella C, Felicioni L, et al : EGFR mutations in non-small-cell lung cancer : analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23 : 857-865, 2005
PubMed
21) Tokumo M, Toyooka S, Kiura K, et al : The relationship between epidemlal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 11 : 1167-1173, 2005
PubMed
22) Bell DW, Lynch TJ, Haserlat SM, et al : Epidermal growth factor receptor mutations and gene amplification in nonsmall-cell lung cancer : Molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23 : 8081-8092, 2005
PubMed
23) Cappuzzo F, Hirsch FR, Rossi E, et al : Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97 : 643-655, 2005
PubMed
24) Hirsch FR, Varella-Garcia M, McCoy J, et al : Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitiVity to gefitinib in patients with bronchioloalveolar carcinoma subtypes : A southwest oncology group study. J Clin Oncol 23 : 6838 & 6845, 2005
 
25) Cappuzzo F, Varella-Garcia M, Shigematsu H, et al : Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal groWth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 23 : 5007-5018, 2005
PubMed
26) Pao W, Wang TY, Riely GJ, et al : KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2 : e17, 2005
PubMed
27) Bailey R, et al : Tumor epidermal growth factor receptor (EGFR) expression levels does not predict for response in patients receiving gefitinib ("Iressa", ZD 1839) monotherapy for pretreated advanced non-small-cell lung cancer : IDEAL 1 and 2. Proc Am Assoc Cancer Res 44 : 1362 [abstr LB-170], 2003
 
28) Cappuzzo F, Magrini E, Ceresoli GL, et al : Akt phosphorylation and gefitinib efficacy in patients with advanced nonsmall-cell lung cancer. J Natl Cancer Inst 96 : 1133-1141, 2004
PubMed
29) Han SW, Hwang PG, Chung DH, et al : Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa(R), ZD 1839) in chemotherapy resistant non-small-cell lung cancer. Int J Cancer 113 : 109-115, 2005
 
30) Giaccone G, et al : A phase III clinical trial of Gefitinib, an EGFR inhibitor, in combination with gemcitabine and cisplatin in advanced non-sma11-cell lung cancer (INTACT 1). J Clin Oncol 22 : 777-784, 2004
 
31) Herbst RS, et al : Gefitinib in Combination With Paclitaxel and Carboplatin in Chemotherapy-Naive Patients With Advanced Non-Small-Cell Lung Cancer : Results from a Phase III Clinical Trial (INTACT 2). J Clin Oncol 22 : 785-794, 2004
PubMed
32) Thatcher N, Chang A, Parikh P, et al : Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer : Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 : 1527-1537, 2005
PubMed
33) Hirsch FR, Varella-Garcia M, Bunn PA, et al : Molecular predictors of outcome with gefitinib in a phase III placebocontrolled study in advanced non-small-cell lung cancer. J Clin Oncol 24 : 5034-5042, 2006
 
34) Niho S, Kubota K, Goto K, et al : First-line single-agent treatment with gefitinib in patients with advanced non-smallcell lung cancer : A phase II study. J Clin Oncol 24 : 64-69, 2006
 
35) Lee DH, Han JY, Lee HG, et al : Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clifl Cancer Res 11 : 3032-3037, 2005
PubMed
36) Inoue A, Suzuki T, Fukuhara T, et al : Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24 : 334 0-3346, 2006
 
37) Kelly K, Gaspar LE, Chansky K, et al : Low incidence of pneumonitis on SWOG OO23 : Apreliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non-small cell lung cancer. J Clin Oncol (ASCO Annual Meeting Abstracts) 23 : [abstr 7058], 2005
 
38) Herbst RS, Prager D, Hermann R, et al : TRIBUTE : A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23 : 5892-5899, 2005
PubMed
39) Gatzemeier U, Pluzanska A, Szczesna A, et al : Results of a phase M trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol, 2004, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22, 14S : [abstr 7010], 2004
 
40) Eberhard DA, Johnson BE, Amler LC, et al : Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23 : 5900-5909, 2005
PubMed
41) Shepherd FA, Pereira JR, Ciuleanu T, et al : Erlotinib in previously treated non-small-cell lung cancer. J Engl J Med 353 : 123-132, 2005
 
42) Tsao M-S, Sakurada A, Cutz J-C, et al : Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 353 : 133-144, 2005
PubMed
43) Marchetti A, Felicioni L, Buttitta F : Assessing EGFR mutations. N Engl J Med 354 : 526-528, 2006
PubMed
44) Hidalgo M, Siu LL, Nemunaitis J, et al : Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19 : 3267-3279, 2001
 
45) アストラゼネカ : イレッサ(R)錠250プロスペクティブ調査 (特別調査) に関する結果と考察 (2004年8月)
 
46) Ohe Y, et al : Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer. European Journal of Cancer 37 : 54-63, 2001
PubMed
47) アストラゼネカ : ゲフィチニブ (イレッサ(R)錠250) の急性肺障害・間質性肺炎 (ILD) に関する専門家会議最終報告 (2003年3月26日)
 
P.220 掲載の参考文献
1) Carmeliet P : "Mechanisms of angiogenesis and arteriogenesis". Nat Med 6 (4) : 389-395, 2000
PubMed
2) Rak JW, St Croix BD, et al : "Consequences of angiogenesis for tumor progression, metastasis and cancer therapy". An ticancer Drags 6 (1) : 3-18, 1995
 
3) Shibuya M : Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct, Funct 26 (1) : 25-33, 2001
PubMed
4) Dvorak HF : "Vascular pemleability factor/vascular endothelial growth factor : a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy". J Clin Oncol 20 (21) : 4368-4380, 2002
 
5) Bevacizumab : Anti-VEGF monoclonal antibody, avastin, rhumab-VEGF. Drugs R D 3 (1) : 28-30, 2002
PubMed
6) Sandler AB, Gray R, Brahmer J, et al : Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC#704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC) : An Eastem Cooperative Oncology Group (ECOG) Trial-E4599. J Clin Oncol 23 (June 1 Suppl.) : 2s (Abstract LBA4), 2005
 
7) Rosen L, Kurzrock R, Jackson E, et al : Safety and pharmacokinetics of AMG 706 in patients with advanced solid tumor. ASCO Meetiflg Abstracts 1 : 3013, 2005
 
8) Blumenschein G Jr, Sandler A, O'Rourke T, et al : Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and carboplatin/paclitaxel (CP) for the treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC) Proc-ASCO Vol 24, No 18S (June 20 Supplement), 2006
 
9) Fujisaka Y, Yamada Y, Yamamoto N, et al : Safety and Pharmacokinetics (PK) of AMG 706 in Japanese Patients with Advanced Solid Tumors. Proc-AACR-NCI-EORTC 55S, 2005
 
10) Wedge SR, Ogilvie DJ, Dukes M, et al : ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oraladmin-istration. Cancer Res 62 : 4645-4655, 2002
 
11) Holden SN, Eckhardt SG, Basser R, et al : Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 16 (8) : 1391-1397, 2005
PubMed
12) Tamura T, Minami H, Yamada Y, et al : A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors. Jburnal of Thoracic Oncology 1 (9) : 1002-1009, 2006
PubMed
13) Nakagawa K, Kiura K, Shinkai T, et al : A randomized double-blind phase II a dose-finding study of ZD6474 in Japanese patients with NSCLC Proc ASCO. Vol 24, No 18S (June 20 Supplement) : 7067, 2006
 
14) Heymach JV, Johnson BE, Prager D, et al : A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC Proc ASCO Vol 24, No 18S (June 20 Supplement) : 7016, 2006
 
15) Natale RB, Bodkin D, Govindan R, et al : ZD6474 versus gefitinib in patients with advanced NSCLC : Final results from a two-part, double-blind, randomized phase ll trial Proc ASCO Vol 24, No 18S (June 20 Supplement) : 7000, 2006
 
16) In vivo antitumor actiVity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors : determination of a pharmacokinetic/pharmacodynamic relationship. Mendel DB, Laird AD, Xin X, et al : Clin Cancer Res 15 ; 12 (20 Pt 1) : 6203-6204, 2006
 
P.226 掲載の参考文献
1) 日本肺癌学会/編 EBMの手法による肺癌診療ガイドライン2005年版 金原出版 東京, 2005
 
2) Bjoraker JA, Ryu JH, Edwin MK, et al : Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 157 : 199-203, 1998
PubMed
3) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編 特発性間質性肺炎診断と治療の手引き 南江堂, 東京 2004
 
4) Hunninghake GW, Zimmemlan MB, Schwartz DA, et al : Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 164 : 193-196, 2001
 
5) Doublas WW, Ryu JH, Schroeader DR. Idiopathic pulmonary fibrosis : impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med 161 : 1172-1178, 2000
 
6) Hertz MI, Boucck MM, Ceng MC, et al : Scientific registry of the International Society for Heart and Lung Transplantation : Introduction to the 2005 Annual Reports. J Heart Lung Transp 24 : 1182-1187, 2005
 
7) Turner-Warwick M, Lebowitz M, Burrows B, et al : Ciyptogenic fibrosing alveolitis and lung cancer Thorax 35 : 496-499, 1980
PubMed
8) Hubbard R, Venn A, Lewis S, Britton J : Lung cancer and cryptogenic fibrosin alveolitis : a population-based cohort study. Am J Respir Crit Care Med 161 : 5-8, 2000
 
9) Samet JM : Does idiopathic pulmonary fibrosis increase lung cancer risk? Am J Respir Crit Care Med 161 : 1-2, 2000
PubMed
10) Park J, Kim DS, Shim TS, Lim CM, Koh Y, Lee SD, et al : Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J 17 : 1216-1219, 2001
 
11) Bouros D, Hatzakis K, Labralds H, Zeibecoglou K : Association of malignancy with diseases causing interstitial pulmonary changes. Chest 121 : 1279-1289, 2002
 
12) Artinian V, Kvale PA : Cancer and interstitial lung disease. Curren t Opinion in Pulmonary Medicine 10 : 425-434, 2004
 
13) Baumgartner KB, Samet JM, Stidley CA, et al : Cigarette smoking : a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 155 : 242-248, 1997
PubMed
14) Hironaka M, Fukayama M : Pulmonary fibrosis and lung carcinoma : a comparative study of metaplastic epithelia in honeycombed areas of usual interstitial pneumonia with or without lung carcinoma. Pathol Int 49 : 1060-1066, 1999
PubMed
15) Aubry MC, Myers JL, Doublas WW, et al : Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis. Mayo Clin Proc 77 : 763-770, 2002
 
16) 岡本竜哉, 一安秀範, 一門和哉・他 : 特発性肺線維症の臨床的検討 急性増悪例の解析. 日本呼吸器学会雑誌 44 : 359-367, 2006
 
17) Kutlu CA, Williams EA, Evans TW, et al : Acute Lung injury and Acute respiratory distress syndrome after pulmonary resection. Ann Thorac Surg 69 : 376-380, 2000
PubMed
18) Bernard GR, Artigas A, Brigham KL, et al : and The Consensus Committee. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant out-comes, and clinical trial coordination. Am J Crit Care Med 149 : 818-824, 1994
 
19) Yueksel M, Oezyurtkan MO, Bostanci K, et al : Acute exacerbation of interstitial fibrosis after pulmonary resection. Ann Thorac surg 82 : 336-338, 2006
 
20) Utz JP, Ryu JH, Douglas WW, et al : High short-term mortality following lung biopsy for usual interstitial pneumonia. Eur Respir J 17 : 175-179, 2001
PubMed
21) Kawasaki H, Nagai K, Yoshida J, et al : Postoperative morbidity, mortality, and survival in lung cancer associated with idiopathic pulmonary fibrosis. J Surg Oncol 81 : 33-37, 2002
PubMed
22) Kumar P, Goldstraw P, Yamada K, et al : Pulmonary fibrosis and lung cancer ; risk and benefit analysis of pulmonary resection. J Thorac Cardiovasc Surg 125 : 1321-1327, 2003
PubMed
23) Okamoto T, Gotoh M, Masuya D, et al : Clinical analysis of interstitial pneumonia after surgery for lung cancer. Jpn J Thorac Cardiovasc Surg 52 : 323-329, 2004
PubMed
24) 渡辺敦, 小柳哲也, 大澤久慶・他 : 間質性肺病変を伴う肺癌手術 とくに非合併例との比較. 胸部外科 58 : 9-14, 2005
 
25) 千田雅之, 高橋博人, 山中秀樹・他 : 限局性間質性肺炎からの肺癌手術後急性増悪例の検討. 胸部外科 58 : 22-25, 2005
 
26) Kondoh Y, Taniguchi H, Kawabata Y, et al : Acute exacerbation in idiopathic pulmonary fibrosis : analysis of clinical and pathological frindings in three cases.ohest 103 : 1808-1812, 1993
PubMed
27) 石井芳樹, 北村諭 : 特発性間質性肺炎急性悪化症例に対する好中球エラスターゼ阻害剤ONO5046の効果-後期第II相試験の成績-厚生省特定疾患呼吸器系疾患調査研究班びまん性肺疾患分科会平成8年度研究報告書. 240-244, 1997
 
28) 田中朋彦, 原田亮, 村木里誌・他 : 間質性肺炎合併肺癌例の術後急性増悪に対する有効な予防法. 胸部外科 58 : 41-45, 2005
 
29) 高岡一彦, 木村文平, 相河朋規・他 : 術前にびまん性肺野陰影を認めた原発性肺癌に対する手術. 胸部外科 58 : 31-35, 2005
 
30) 矢野篤次郎, 古賀聡 肺癌手術におけるステロイド予防投与-術後間質性肺炎予防に向けて. 胸部外科 58 : 37-40, 2005
 
31) 埴淵昌毅, 山口俊彦, 岡田達也・他 : 特発性間質性肺炎 (IIP) 合併肺癌に対する肺癌治療後IIP急性増悪症例の臨床的検討. 肺癌 41 : 281-286, 2001
 
32) 一瀬幸人, 坪井正博, 横田総一郎・他 : ゲフィチニブのコホート内ケースコントロールスタディ-ILDの相対リスクおよび危険因子の検討-. 肺癌 46 : 446, 2006
Medical*Online
33) Chiyo M, Sekine Y, Iwata T, et al : Impact of interstitial lung disease on surgical morbidity and mortality for lung cancer : analyses of short-term and long-term outcomes. J Thorac Cardiovasc Surg 126 : 1141-1146, 2003
PubMed
34) Fujimoto T, Okazaki T, Matsukura T, Hanawa T, Yamashita N, Nishimura K, et al : Operation for lung cancer in patients with idiopathic pulmonary fibrosis : surgical contraindication? Ann Thorac Surg 76 : 1674-1679, 2003
PubMed
35) Dheda K, Lalloo UG, Cassim B, et al : Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumato1 23 : 306-309, 2004
PubMed
36) Dawson JK, Fewins HE, Desmond J, et al : Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 56 : 622, 2001
PubMed
37) Peters-Golden M, Wise RA, Hochberg M, et al : Incidence of lung cancer in systemic sclerosis. J Rheumatol 12 : 1136-1139, 1985
PubMed
38) Roumm AD, Medsger TA Jr. Cancer and systemic sclerosis : an epidemiologic study. Arthritis Rheum 28 : 1336-1340, 1985
PubMed
39) Nakajima J, Takamoto S, Murakawa T, et al : Is interstitial pneumonia in patients with collagen diseases a contraindication to lung cancer surgery? Surg Today 37 : 14-18, 2007
PubMed
P.234 掲載の参考文献
1) Adjei AA : Pemetrexed (Alimta) : a novel multitargeted antifolate agent. Expert Rev Anticancer Ther 3 : 145-156, 2003
PubMed
2) McDonald AC, Vasey PA, Adams L, et al : A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin Cancer Res 4 : 605-610, 1998
 
3) Rinaldi DA, Burris HA, Dorr FA, et al : Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 13 : 2842-2850, 1995
PubMed
4) Cripps C, Burnell M, Jolivet J, et al : Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer : an NCIC Clinical Trials Group study. Ann Oncol 10 : 1175-1179, 1999
PubMed
5) Rusthoven JJ, Eisenhauer E, Butts C, et al : Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer : A phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17 : 1194-1199, 1999
 
6) Clarke SJ, Abratt R, Goedhals L, et al : Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapynaive patients with advanced non-smal1-cell lung cancer. Ann Oncol 13 : 737-741, 2002
PubMed
7) Smit EF, Mattson K, von Pawel J, et al : ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer : a phase II study. Ann Oncol 14 : 455-460, 2003
PubMed
8) Hanna N, Shepherd FA, Fossella FV, et al : Randomized phase M trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 : 1589-1597, 2004
 
9) Weiss GJ, Langer C, Rosell R, et al : Elderly patients benefit from second-line cytotoxic chemotherapy : a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 24 : 4405-4411, 2006
PubMed
10) Nakagawa K, Kudoh S, Matsui K : A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. Br J Cancer Sep 18 ; 95 (6) : 677-682, 2006
 
11) Vogelzang NJ, et al : Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 : 2636-2644, 2003
PubMed
12) Yamada Y, Hamaguchi T, Goto M, et al : Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infUsion of 5-fluorouracil. Br J Cancer 89 : 816-820, 2003
 
13) Ajani JA, Faust J, Ikeda K, et al : Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 23 : 6957-6965, 2005
PubMed
14) Shirao K, Hoff PM, Ohtsu A, et al : Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer : joint United States and Japan study of UFT/LV. J Clin Oncol 22 : 3441-3442, 2004
 
15) Furuse K et al : Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non small lung cancer. Int J Clin Oncol 6 : 236-241, 2001
 
16) Kawahara M, et al : Phase II study of S-1, a novel oral fluoropyrimidine, for advanced non small lung cancer. Br J Cancer 85 : 939-943, 2001
PubMed
17) Ichinose Y, et al : S-1 plus cisplatin combination chemotherapy in patients with advanced non small lung cancer : a multi institutional phase II trial. Clin Cancer Res 10 : 7860-7864, 2004
PubMed
18) Ohe Y, Ohashi Y, Kubota T, et al : Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer : Four-arm cooperative study in Annals of Oncol advance published November 1, 2006
 
19) Endo M, Yamamoto N, Sakai H, et al : Phase II study of 3 weekly S-1 plus cisplatin in patients with advanced nonsmall-cell lung cancer (NSCLC), S-1 cooperative study group. ESMO : 752P, 2006
 
20) Ohtsu A, et al : Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 17 : 2915-2921, 1999
 
21) Herskovic A, et al : Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of esophagus. N Eng J Med 326 : 1593-1598, 1992
 
22) Choy H, Akerley W, Safran H, et al : Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 16 : 3316-3322, 1998
PubMed
23) Choy H, Safran H, Akerley W, et al : Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res 4 : 1931-1936, 1998
PubMed
24) Vokes EE, Hemdon JE, 2nd, Crawford J, et al : Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer : cancer and leukemia group B study 9431. J Clin Oncol 20 : 4191-4198, 2002
 
25) Browder T, Butterfield CE, Kraling BM, et al : Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60 : 1878-1886, 2000
PubMed
26) Klement G, Baruchel S, Rak J, et al : Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105 : R15-24, 2000
PubMed
27) Basaki Y, Aoyagi K, Chikahisa L, et al : UFT and its metabolites inhibit cancer-induced angiogenesis. Via a VEGF-related pathway. Oncology (Williston Park) 14 (10 Suppl 9) : 68-71, 2000
 
28) Munoz R, Shaked Y, Bertolini F, et al : Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. Breast 14 : 466-479, 2005
PubMed
29) Pietras K, Hanahan D : Amultitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and surVival benefit in a mouse model of cancer. J Clin Oncol 23 : 939-952, 2005
 
P.242 掲載の参考文献
1) Non-small Cell lung cancer Collaborative Group : chemotherapy in non-small cell lung cancer : a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311 : 899-909, 1995
 
2) Kubota K, Furuse K, Kowahara M, et al : Role of Radiotherapy in Combined Modality Treatment of Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 12 : 1547-1552, 1994
 
3) Fruse K, Fukuoka M, Kawahara M, et al : Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 17 : 2692-2699, 1999
 
4) Curran WJ, Scott CB, Langer CL, et al : Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC : RTOG 9410. Proc Am Soci J Clin Oncol 22 : 621, 2003
 
5) Fournel P, Robinet G, Thomas P, et al : Randomized phase In trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer : Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 9501 Study. J Clin Oncol 23 : 5910-5917, 2005
 
6) Zatloukal P, Petruzelka L, Zemanova M, et al : Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer : a randomized study. Lung Cancer 46 : 87-98, 2004
PubMed
7) Gandara DR, Chansky K Albain KS, et al : Consolidation Docetaxel After Concurrent Chemoraditherapy in Stage IIIB Non-Small-Cell Lung Cancer : Phase n Southwest Oncology Group Study S9504. J Clin Oncol 21 : 2004-2010, 2003
 
8) Sekine I, Noda K Oshita F, et al : Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable Stage III Bnon-small cell lung cancer. Cancer Sci 95 : 691-695, 2004
 
9) Sekine I, Nokihara H, Sumi M, et al : Docetaxel Consolidation Therapy Following Cisplatin, Vinorelbine, and Concurrent Thoracic Radiothrapy in Patients with Unresectable Stage IIIB Non-Small-Cell Lung Cancer. J Thora Oncol 1 : 810-815, 2006
 
10) Sause W, Kolerar P, Taylor S, et al : Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer : Radiation Therapy Oncology Group, Eastem Cooperative Oncology Group, and Southwest Oncology Group.ohest 117 : 358-364, 2000
 
11) Schild SE, Stella PJ, Geyer SM, et al : Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 54 : 370-378, 2000
PubMed
12) Ohe Y, Ishizuka N, Tamura T, et al : long-teml follow-up of patients with unresectable locally advanced non-small cell lung cancer treated with chemoradiotherapy : a retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG 0003A). Cancer Sci 94 : 729-734, 2003
 
13) Saunders M, Dische S, Barrett A, et al : Continuous hyperfractionated accelerated radiotherapy (CHART) versus convendonal radiotherapy in non-small-cell lung cancer : a randomised multicentre trial. CHART Steering Committee. Lancet 350 : 161-165, 1997
 
14) Belani CP, Wang W, Johnson DH, et al : Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597) : induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage III Aand B non-small-cell lung cancer. J Clin Oncol 23 : 3760-3767, 2005
PubMed
15) Bradley J, Graham MV, Winter K, et al : Toxicity and outcome result of RTOG 9311 : a phase I-II dose-escalation study using three- dimensional conformal radiotherapy in patients With in operable non-small cell lung carcinoma. Int J Rdiat Oncol Biol Phys 61 : 318-328, 2005
 
16) Chinnaiyan P, Huang S, Vallabhaneni G, et al : Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 65 : 3328-3335, 2005
PubMed
17) Bonner JA, Harari PM, Giralt J, et al : Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 9 : 567-578, 2006
PubMed
18) Kelly K, Gaspar LE, Chansky K et al : Low incidence of pneumonitis on SWOG 0023 : A preliminary analysis of an on going phase In trial of concurrent chemoradiotherapy follwed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non-small cell lung cancer. Proc Am soc Clin Oncol 23 : 634s, 2005
 
19) N Ready, p Janne, J Herndon, et al : Chemoradiotherapy (CRT) and gefitinib (G) in stage III non-small cell lung cancer (NSCLC) : A CALGB stratified phase II trial. Proc Am soc Clin Oncol 24 : 18s, 2006
 
20) Mauceri HJ, Hanna NN, Beckett MA, et al : Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394 : 287, 1998
PubMed
21) Crane CH, Ellis LM, Abbruzzese JL, et al : Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 24 : 1145-1151, 2006
PubMed
22) Merchant JJ, Kim K, Mehta MP, et al : Pilot and safety trial of carboplatin, paclitaxel, and thalidomide in advanced non-small-cell lung cancer. Clin Lung Cancer 2 : 48-52, 2000
PubMed

診断・治療 ( 中皮腫, 胸膜・縦隔腫瘍 )

P.253 掲載の参考文献
1) Concensus report Asbestos, asbestosis, and cancer : the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health 23 : 311-316, 1997
 
2) 森永謙二 : 石綿関連疾患の疫学. Mebio 23 : 12-20, 2006
Medical*Online
3) Morinaga K, Kishimoto T, Sakatani M, et al : asbestos-related lung cancer and mesothelioma in Japan. Ind Health 39 : 65-74, 2001
PubMed
4) Wagner JC, Sleggs CA, Marchand P : Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 17 : 260-271, 1960
PubMed
5) McDonald AD, McDonald JC : Epidemiology of malignant mesothehoma. In : Antman K Aisner J eds. Asbestos-related Malignancy Orland, Grune and Stratton, 31-55, 1987
 
6) Klelkowski D, Nelson G, Ree D : Risk of mesothelioma from exposure to crocidolite asbestos : a 1995 update of a South Africa mortality study. Occup En Viron Med 57 : 563-567, 2000
 
7) Beny G, Newhouse MI, Wagner JC : Mortality from all cancers of asbestos factory workers in east London 1933-1980. Occup Environ Med 57 : 782-785, 2000
 
8) Roushdy-Hammady I, Siegel J, Emri S, et al : Genetic-susceptibity factor and malignant mesothelioma in the Cappadocian region of Turkey. Lan cet 357 : 444-445, 2001
 
9) Bang KM, Pinheiro GA, Wood JM, et al : Malignant mesothelioma mortality in the United States, 1999-2001. Int J Occup En Viron Health 12 : 9-15, 2006
 
10) Pistolest M, Rusthoven J : Malignant pleural mesothelioma-update, current management, and newer therapeutic strategies-. Chest 126 : 1318-1329, 2004
 
11) Neumann V, Gunther S, Muller KM, et al : Malignant mesohelioma-Gerrnan mesothelioma register 1987-1999. Int Arch Occup Environ Health 74 : 383-395, 2001
 
12) Bianchi C, Brollo A, Ramani L, et al : Malignant mesothelioma in Europe. Int J Med Environ 28 : 103-107, 2000
 
13) Leigh J, Davidson P, Hendrie L, et al : Malignant mesothelioma in Australia, 1945-2000. Am J Ind Med 41 : 189-201, 2002
 
14) 車谷典男, 熊谷信二 : わが国の胸膜中皮腫の記述疫学. THE LUNG perspectives 14 : 267-271, 2006
Medical*Online
15) 岸本卓巳, 青江啓介, 玄馬顕一 : 平成17年度厚生労働科学特別研究 中皮腫と職業性アスベストばく露に関する研究報告書, 1-26, 2006
 
16) 岸本卓巳, 木村清延, 宇佐美郁治・他 : 我が国における中皮腫の臨床像-労働者健康福祉機構・労災病院グループ自験症例132例のまとめ, アスベスト曝露によって発生する肺がんと中皮腫に関する研究報告書, 6-19, 2006
 
17) 森永謙二 : 中皮腫トピックス 疫学. 日胸 65 : 587-593, 2006
 
18) Peto J, Decarli A, La Vecchla, et al : The European mesothelioma epidemic. Br J Cancer 79 : 666-672, 1999
 
19) Peto J, Hodgson Jt, Marthew FE, et al : Continuing increase in mesothelioma mortality in Britain. Lancet 345 : 535-539, 1995
 
20) Murayama T, Takahashi K, Natori H, et al : Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model. Am J Ind Med 49 : 1-7, 2006
 
P.262 掲載の参考文献
1) Rusch W : A proposed new international TNM staging system for malignant pleural mesothelioma. From the Intemational Mesothelioma Interest Group. Chest 108 : 1122-1128, 1995
 
2) Robinson BWS, Lake RA : Advances in malignant mesothelioma. N Engl J Med 353 : 1591-1603, 2005
PubMed
3) 森永謙二編 : 職業性石綿ばく露と石綿関連疾患. 基礎知識と労災補償- (改訂新版). 三信図書, 東京, 2005
 
4) 独立行政法人労働者健康福祉機構編 : アスベスト関連疾患日常診療ガイド. アスベスト関連疾患を見逃さないために. 増補改訂版, 労働調査会, 東京, 2006
 
5) British Thoracic Society Standards of Care Committee. Statement on malignant mesothelioma in the United Kingdom. Thorax 56 : 250-265, 2001
PubMed
6) Whitaker D : The cytology of malignant mesothelioma. Cytopathology 1 1 : 139-151, 2000
 
7) Saad RS, Cho P, Liu YL, et al : The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma : a comparative study. Desig Cytopath 32 : 156-159, 2005
 
8) Robinson BWS, Creaney J, Lake RA, et al : Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362 : 1612-1616, 2003
 
9) Pass HI, Lott D, Lonardo F, et al : Asbesotos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353 : 1564-1573, 2005
PubMed
10) Hiraki A, Aoe K, Ueoka H : Asbestos exposure and serum osteopontin. N Engl J Med 354 : 304-305, 2006
PubMed
11) Aoe K, Hiraki A, Maeda T, et al : Soluble receptor-binding cancer antigen expressed on SiSo cells (RCAS1) in pleural fluid : A potential diagnostic marker for malignant pleural effusion. Chest 126 : 1195-1197, 2004
PubMed
12) Hiraki A, Aoe K Murakami T, et al : Expression of the tumor-associated antigen RCASI and its soluble protein in pleural fluid in malignant mesothelioma. Oncol Rep 14 : 357-362, 2005
 
13) Singhal S, Wiewrodt R, Malden LD, et al : Gene expression profiling of malignant mesothelioma. Clin Cancer Res 9 : 3080-3097, 2003
PubMed
14) Gordon GJ, Jensen RV, Hsiao LL, et al : Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res 62 : 4963-4967, 2002
PubMed
P.273 掲載の参考文献
1) 森永謙二, 井内康輝・他 : 石綿による健康被害に係る医学的判断に関する考え方報告書 (石綿による石綿被害に係る医学的判断に関する検討会による), 平成18年2月
 
2) 森永謙二, 井内康輝・他 : 悪性 (胸膜) 中皮腫に関するアンケート調査報告書 (平成15年度厚生労働省がん研究助成金による), 2004年2月11日
 
3) 岸本卓己, 井内康輝・他 : 中皮腫と職業性石綿ばく露に関する研究報告書 (平成17年度厚生労働科学特別研究による), 平成18年3月
 
4) Kushitani K Takeshima Y, Inai K, et al : Immunohistochemical panels for distinguishing between epithelioid malignanat mesothelioma and pulmonary adenocarcinoma. Pathol Int, 2007 (in press)
 
5) Kushitani K, Takeshima Y, Inai K, et al : Differential diagnosis between sarcomatoid mesothelioma and sarcoma, sarcomatoid carcinoma, (in submitted)
 
6) Churg A, Roggi V, Inai K, et al : Mesothelioma, in WHO CIassification of Tumours, Pathology & Genetics, Tumours of the lung, pleura, thymus and heart (Edit. By Travis WD et al), IARC Press, Lyon, 129-136, 2004
 
7) Miettinen M, Limon J, Niezabitowski A, et al : Calretinin and other mesothelioma markers in synovial sarcoma. Analysis of antigenic similarities and differences with malignant mesothelioma. Am J Surg Pa thol 25 : 610-617, 2001
 
8) US-Canadian mesothelioma reference panel : The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 24 : 1183-1200, 2000
 
9) Inai K, et al : Pathology of malignant mesothelioma Ed, by Galateau-Salle F, Springer, Berlin, 2005
 
10) Churg A, Cagle PT, Roggli VL : AFIP Atlas of tumor pathology, Series 4, Tumors of the serosal membranes, ARP Press Silver Spring, Maryland, 83-101, 2006
 
11) Attanoos RL, Griffin A, Gibbs AR : The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology 43 : 231-238, 2003
PubMed
P.279 掲載の参考文献
1) 立山義朗, 山本篤志, 栗原寛治, 他 : 最近の194剖検例における肺内のアスベストに関する所見. 広島医学 42 : 878-885, 1989
 
2) 神山宣彦 : 中皮腫における石綿曝露状況の分析法. 病理と臨床 22 : 667-674, 2004
Medical*Online
3) 井内康輝 : アスベスト曝露と関連する胸膜・肺腫瘍. 検査と技術 34 : 704-707, 2006
 
4) 岸槌健太郎 : ヒト肺内に沈着するアスベスト繊維の分析-殊に肺癌, 悪性中皮腫発生との相関. 広大医学 43 : 279-295, 1995
 
5) Hino O, Kobayashi E, Nishizawa M, et al : Renal carcinogenesis in the Eker rat. J Cancer Res Clin Oncol 121 : 602-605, 1995
 
6) Yamashita Y, Yokoyama M, Kobayashi E, et al : Mapping and determination of the cDNA sequence of the Erc gene preferentially expressed in renal cell carcinoma in the Tsc2 gene mutant (Eker) rat model. Biochem Biophys. Res Commun 275 : 134-140, 2000
PubMed
7) Hino O : Hereditary renal carcinogenesis fitting Knudson! s two-hit model : genotype, environment, and phenotype. Gefles Chromosomes Cancer 38 : 357-367, 2003
 
8) Hino O : Multistep renal carcinogenesis in the Eker (Tsc 2 gene mutant) rat model. Current Molecular Medicine 4 : 807-811, 2004
PubMed
9) 樋野興夫 : アスベスト救済. 読売新聞「論点」2005年10月27日付
 
10) 樋野興夫 : アスベスト・中皮腫より発がんを考える. 新農林技術新聞. 2005年12月15日付
 
11) 樋野興夫 : Asbestos-related mesothelioma ("Asbestoma") の血液診断. Human Scence, 2006 (印刷中)
 
12) 樋野興夫 : アスベスト・中皮腫の実態と診療・検査の実情. モダンメディア, 2006 (印刷中)
 
13) 樋野興夫 : 中皮腫トピックス 血液検査-早期診断を目指して-. 日本胸部臨床 2006 (印刷中)
 
14) 樋野興夫 : 胸膜悪性中皮腫血清マーカーについて. とくに, 中皮腫の血清マーカーについて. 呼吸器科, 2006 (印刷中)
 
15) 樋野興夫 : アスベストの検査法は? -とくに, 中皮腫の血清マーカーについて. 検査と技術, 2006 (印刷中)
 
16) Medical Ashai 2006年10月号 1921.
 
17) 樋野興夫 : アスベストと中皮腫 (亀井敏昭, 他監修), 第12章マーカーからみた中皮腫診断の考え方. 篠原出版新社, 東京, 2007 (印刷中)
 
18) 樋野興夫 : 中皮腫の血清診断マーカーの考え方. 最新医学 (印刷中)
 
19) Shiomi K, Miyamoto H, Segawa T, et al : A novel ELISA system for detection of a "N-ERC/Mesothelin" in the sera of mesothelioma patients. Cancer Sci 97 : 928-932, 2006
 
20) Maeda M, Hino O : Molecular tumor markers for Asbestos-related mesothelioma ; Especially serum diagnostic markers. Pathology International 56 : 649-654, 2006
PubMed
P.289 掲載の参考文献
1) Carbone M, Kratzke RA Testa JR : The pathogenesis of mesothelioma. Semin Oncol 29 : 2-17, 2002
PubMed
2) Sandberg AA, Bridge JA : Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Mesothelioma. Cancer Genet Cytogenet 127 : 93-110, 2001
PubMed
3) Musti M, Kettunen E, Dragonieri S, et al : Cytogenetic and molecular genetic changes in malignant mesothelioma. Cancer Genet CYtogenet 170 : 9-15, 2006
PubMed
4) Yang CT, You L, Yeh CC, et al : Adenovirus-mediated p14 (ARF) gene transfer in human mesothelioma cells. J Natl Cancer Inst 92 : 636-641, 2000
 
5) Cote RJ, Jhanwar SC, Novick S, et al : Genetic alterations of the p53 gene are a feature of malignant mesotheliomas. Cancer Res 51 : 5410-5416, 1991
PubMed
6) Carbone M, Rizzo P, Grimley PM, et al : Simian virus-40 large-T antigen binds p53 in human mesotheliomas. Nat Med 3 : 908-912, 1997
PubMed
7) Segers K, Backhovens H, Singh SK et al : Immunoreactivity for p53 and mdm2 and the detection of p53 mutations in human malignant mesothelioma. Virchows Arch 427 : 431-436, 1995
PubMed
8) Whitson BA, Kratzke RA : Molecular pathways in malignant pleural mesothelioma. Cancer Lett 239 : 183-189, 2006
PubMed
9) Park S, SchalHng M, Bernard A, et al : The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat Genet 4 : 415-420, 1993
 
10) Kumar- Singh S, Segers K Rodeck U, et al : WT1 mutation in malignant mesotheHoma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis. J Pathol 181 : 67-74, 1997
PubMed
11) Ordonez NG : Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol 24 : 598-606, 2000
PubMed
12) Mossman BT, Gruenert DCI SV40, growth factors, and mesothelioma : another piece of the puzzle. Am J Respir Cell Mol Biol 26 : 167-170, 2002
 
13) Gazdar AF, Butel JS, Carbone M : SV40 and human tumours : myth, association or causality? Nat Rev Cancer 2 : 957-964, 2002
PubMed
14) Whitson BA, Jacobson BA, Frizelle S, et al : Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Thoracic Surgery Directors Association Resident Research Award. Ann Thorac Surg 82 : 996-1001 ; discussion 1001-1002, 2006
 
15) Versnel MA, Claesson-Welsh L, Hammacher A, et al : Human malignant mesothelioma cell lines express PDGF betareceptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors. Oncogene 6 : 2005-2011, 1991
PubMed
16) Langerak AW, De Laat PA, Van Der Linden-Van Beurden CA, et al : Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo. J Pathol 178 : 151-160, 1996
PubMed
17) Gerwin BI, Lechner JF, Reddel RR, et al : Comparison of production of transforming growth factor-beta and plateletderived growth factor by normal human mesothelial cells and mesothelioma cell lines. Cancer Res 47 : 6180-6184, 1987
PubMed
18) Edwards JG, Swinson DE, Jones JL, et al : EGFR expression : Associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 54 : 399-407, 2006
PubMed
19) Dazzi H, Hasleton PS, Thatcher N, et al : Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed parafirin embedded tissue and the F4, monoclonal antibody. Br J Cancer 61 : 924-926, 1990
PubMed
20) Yang H, Bocchetta M, Kroczynska B, et al : TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA 103 : 10397-10402, 2006
 
21) Marzo AL, Fitzpatrick DR, Robinson BW, et al : Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res 57 : 3200-3207, 1997
PubMed
22) Langerak AW, van der Linden-van Beurden CA, Versnel MA : Regulation of differential expression of platelet-derived growth factor alpha-and beta-receptor mRNA in normal and malignant human mesothelial cell lines. Biochim Biophys Acta 1305 : 63-70, 1996
PubMed
23) Segers K, Ramael M, Singh SK, et al : Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium. Virchows Arch 424 : 631-634, 1994
PubMed
24) Soini Y, Kinnula V, Kaarteenaho-Wiik R, et al : Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma. Clin Cancer Res 5 : 3508-3515, 1999
PubMed
25) Falleni M, Pellegrini C, Marchetti A, et al : Quantitative evaluation of the apoptosis regulating genes Survivin, Bcl-2 and Bax in inflammatory and malignant pleural lesions. Lung Cancer 48 : 211-216, 2005
PubMed
26) Narasimhan SR, Yang L, Gerwin BI, et al : Resistance of pleural mesothelioma cell lines to apoptosis : relation to expression of Bcl-2 and Bax. Am J Physiol 275 : L165-171, 1998
 
27) Schena M, Shalon D, Davis RW, et al : Quantitative monitoring of gene expression pattems with a complementary DNA microarray. Science 270 : 467-470, 1995
 
28) Rihn BH, Mohr S, McDowell SA, et al : Differential gene expression in mesothelioma. FEBS Lett 480 : 95-100, 2000
PubMed
29) Kettunen E, Nissen AM, Ollikainen T, et al : Gene expression profiling of malignant mesothelioma cell lines : cDNA array study. Int J Cancer 91 : 492-496, 2001
PubMed
30) Mohr S, Keith G, Galateau-Salle F, et al : Cell protection, resistance and invasiveness of two malignant mesotheliomas as assessed by 10K-microarray. Biochim Biocphys Acta 1688 : 43-60, 2004
PubMed
31) Hoang CD, D'Cunha J, Kratzke MG, et al : Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest 125 : 1843-1852, 2004
PubMed
32) Wali A, Morin PJ, Hough CD, et al : Identification of intelectin overexpression in malignant pleural mesothelioma by serial analysis of gene expression (SAGE). Lung Cancer 48 : 19-29, 2005
 
33) Pass HI, Liu Z, Wali A, et al : Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res 10 : 849-859, 2004
PubMed
34) Singhal S, Wiewrodt R, Malden LD, et al : Gene expression profiling of malignant mesothelioma. Clin Cancer Res 9 : 3080-3097, 2003
PubMed
35) Sun X, Wei L, Liden J, et al : Molecular characterization of tumour heterogeneity and malignant mesothelioma cell differentiation by gene profiling. J Pathol 207 : 91-101, 2005
 
36) Mohr S, Bottin MC, Lannes B, et al : Microdissection, mRNA amplification and microarray : a study of pleural mesothelial and malignant mesothelioma cells. Biochimie 86 : 13-19, 2004
PubMed
37) Kettunen E, Vivo C, Gattacceca F, et al : Gene expression profiles in human mesothelioma cell lines in response to interferon-gamma treatment. Cancer Genet Cytogenet 152 : 42-51, 2004
PubMed
38) Kettunen E, Nicholson AG, Nagy B, et al : L1CAM, INP10, P-cadherin, tPA and ITGB40ver-expression in malignant pleural mesotheliomas revealed by combined use of cDNA and tissue microarray. Carcinogenesis 26 : 17-25, 2005
PubMed
39) Gordon GJ, Jensen RV, Hsiao LL, et al : Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res 62 : 4963-4967, 2002
PubMed
40) Gordon GJ, Rockwell GN, Godfrey PA, et al : Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin Cancer Res 11 : 4406-4414, 2005
PubMed
41) Gordon GJ, Rockwell GN, Jensen RV, et al : Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol 166 : 1827-1840, 2005
PubMed
42) Lopez-Rios F, Chuai S, Flores R, et al : Global gene expression profiling of pleural mesotheliomas : overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 66 : 2970-2979, 2006
PubMed
43) Gordon GJ, Jensen RV, Hsiao LL, et al : Using gene expression ratios to predict outcome among patient with mesothelioma. J Natl Cancer Inst 95 : 598-605, 2003
PubMed
44) Borczuk AC, Cappellini GC, Kim HK, et al : Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors. Oncogene 26 : 610-617, 2007
PubMed
45) Davidson B, Zhang Z, Kleinberg L, et al : Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin Cancer Res 12 : 5944-5950, 2006
PubMed
P.304 掲載の参考文献
1) Butchart EG, Ashcroft T, Barnsley WC, et al : Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax 31 (1) : 15-24, 1976
PubMed
2) Rusch W : Aproposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 108 (4) : 1122-1128, 1995
 
3) Sugarbaker DJ, Flores RM, Jaklitsch MT, et al : Resection margins, extrapleural nodal status, and cell type determine postoperative long-tem survival in trimodality therapy of malignant pleural mesothelioma : results in 183 patients. J Thorac Cardiovasc Surg 117 (1) : 54-63, 1999
 
4) British Thoracic Society Standards of Care Committee : Statement on malignant mesothelioma in the United
PubMed
5) van Meerbeeck Jp, Boyer M : Consensus report : pretreatment minimal staging and treatment of potentially resectable malignant pleural mesothelioma. Lung Cancer 49 (Suppl 1) : S123-127, 2005
 
6) Sugarbaker DJ, Mentzer SJ, Strauss G : Extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma. Ann Thorac Surg 54 (5) : 941-946, 1992
PubMed
7) Worn H : Chances and results of surgery of malignant mesothelioma of the pleura. Thoraxchir Vask Chir 22 (5) : 391-393, 1974
PubMed
8) Rusch VW : Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma. Chest 103 (4 Suppl) : 382S-384S, 1993
 
9) Waller DA, Morritt GN, Forty J : Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion. Chest May 107 (5) : 1454-1456, 1995
PubMed
10) Sugarbaker DJ, Strauss GM, Lynch TJ, et al : Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol 11 (6) : 1172-1178, 1993
PubMed
11) Rusch W, Venkatraman ES : Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 68 (5) : 1799-1804, 1999
 
12) Takagi K, Tsuchiya R, Watanabe Y : Surgical approach to pleural diffuse mesothelioma in Japan. Lung Cancer 31 : 57-65, 2001
PubMed
13) 東山聖彦, 森永謙二, : 全国アンケート調査によるわが国の悪性胸膜中皮腫に対する外科治療成績. 胸外 60 (1) : 19-24, 2007
 
14) 西英行, 鷲尾一浩, 玄馬顕一・他 : 悪性胸膜中皮腫に対する胸膜肺全摘術. 肺癌 46 : 195-198, 2006
Medical*Online
15) Huncharek M, Kelsey K, Mark EJ, et al : Treatment and survival in diffuse malignant pleural mesothelioma ; a study of 83 cases from the Massachusetts General Hospital. Anticancer Res 16 (3A) : 1265-1268, 1996
PubMed
16) Ceresoli GL, Locati LD, Ferreri AJ, et al : Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer 34 (2) : 279-287, 2001
PubMed
17) Maruyama R, Shoji F, Okamoto T, et al : Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma. Jpn J Clin Oncol 35 (8) : 433-438, 2005
PubMed
18) Rusch W, SaltZ L, Venkatraman E, et al : A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol 12 (6) : 1156-1163, 1994
 
19) Colleoni M, Sartori F, Calabro F, et al : Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma. Tumori 82 (1) : 53-56, 1996
PubMed
20) Ratto GB, Civalleri D, Esposito M, et al : Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma : a feasibility and pharmacokinetic study. J Thorac Cardiovasc Surg 117 (4) : 759-765, 1999
PubMed
21) Sugarbaker D, Zellos L, Capalbo L, et al : Clinical results of phase I trial of intraoperative intracavitary hyperthermic chemotherapy with EPP for MPM. Proc Am Soc Clin Oncol 20 : 370a (absta 2094), 2001
 
22) van Ruth S, Baas P, Haas RL, et al : Cytoreductive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy for stage I malignant pleural mesothelioma. Ann Surg Oncol 10 (2) : 176-182, 2003
 
23) Richards WG, Zellos L, Bueno R, et al : Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol 24 (10) : 1561-1567, 2006
PubMed
24) Kodama K, Doi O, Tatsuta M, et al : Development of postoperative intrathoracic chemo-themlotherapy for lung cancer with objective of improving local cure. Cancer 64 (7) : 1422-1428, 1989
PubMed
25) Lu C, Perez-Soler R, Piperdi B, et al : Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. J Clin Oncol 23 (15) : 3495-3501, 2005
PubMed
26) Moskal TL, Dougherty TJ, Urschel JD, et al : Operation and photodynamic therapy for pleural mesothelioma : 6-year follow-up. Ann Thorac Surg 66 (4) : 1128-1133, 1998
PubMed
27) Pass HI, Temeck BK, Kranda K, et al : Phase M randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol 4 (8) : 628-633, 1997
PubMed
28) Baas P, Murrer L, Zoetmulder FA, et al : Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies. Br J Cancer 76 (6) : 819-826, 1997
PubMed
29) Friedberg JS, Mick R, Stevenson J, et al : A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma. Ann Thorac Surg 75 (3) : 952-959, 2003
 
30) Hilaris BS, Nori D, Kwong E, et al : Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 10 (3) : 325-331, 1984
PubMed
31) Gupta V, Mychalczak B, Krug L, et al : Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 63 (4) : 1045-1052, 2005
PubMed
32) Lee TT, Everett DL, Shu HK, et al : Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 124 (6) : 1183-1189, 2002
PubMed
33) Maasilta P, Kivisaari L, Holsti LR, et al : Radiographic chest assessment of lung injury following hemithorax irradiation for pleural mesothelioma. Eur Respir J 4 (1) : 7683, 1991
 
34) Sugarbaker DJ, Garcia Jp, Richards WG, et al : Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann Surg 224 (3) : 288-294, 1996
PubMed
35) Baldini EH, Recht A, Strauss GM, et al : Pattems of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 63 (2) : 334-338, 1997
 
36) Rusch VW, Rosenzweig K, Venkatraman E, et al : A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 122 (4) : 788-795, 2001
PubMed
37) Yajnik S, Rosenzweig KE, Mychalczak B, et al : Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 56 (5) : 1319-1326, 2003
PubMed
38) Forster KM, Smythe WR, Starkschall G, et al : Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma : clinical implementation. Int J Radiat Oncol Biol Phys 55 (3) : 606-616, 2003
PubMed
39) Ahamad A, Stevens CW, Smythe WR, et al : Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. Cancer J 9 (6) : 476-484, 2003
 
40) Allen AM, Czerminska M, Janne PA, et al : Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 65 (3) : 640-645, 2006
PubMed
41) Weder W, Kestenholz P, Taverna C, et al : Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 22 (17) : 3451-3457, 2004
PubMed
42) Flores RM, Krug LM, Rosenzweig KE, et al : Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma : A phase II trial. J Thorac Oncol 1 : 289-295, 2006
PubMed
43) Pagan V, Ceron L, Paccagnella A, et al : 5-year prospective results of trimodality treatment for malignant pleural mesothelioma. J Cardiovasc Surg ITorino) 47 (5) : 595-601, 2006
PubMed
44) 岡田守人 : 悪性胸膜中皮腫に対する外科療法. 日胸 65 (7) : 646-650, 2006
Medical*Online
45) 河野朋哉, 寺町政美, 森英恵・他 : 悪性胸膜中皮腫に対する集学的治療の検討. 日呼外会誌 20 (2) : 20-25, 2006
 
46) Steele JPC, Klabatsa A, Fennell DA, et al : Prognostic factors in mesothelioma. Lung Cancer 49S1 : S9-S52, 2005
 
47) Rusch VW, Piantadosi S, Holmes EC : The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. J Thorac Cardiovasc Surg 102 (1) : 1-9, 1991
 
P.313 掲載の参考文献
1) Gordon W Jr., Antman KH, Greenberger JS, et al : Radiation therapy in the management of patients with mesothelioma. Int J Radiat Oncol Biol Phys 8 : 19-25, 1982
 
2) de Graaf-Strukowska L, van der Zee J, van Putten W, et al : Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura-a single-institution experience with 189 patients. Int J Radiat Oncol Biol Phys 43 : 511-516, 1999
PubMed
3) Bissett D, Macbeth FR, and Cram I : The role of palliative radiotherapy in malignant mesothelioma. Clin Oncol (R Coll Radiol) 3 : 315-317, 1991
PubMed
4) British Thoracic Society Standerds Care Committee : Statement on malignant mesothelioma in the United Kingdom. Thorax 56 : 250-265, 2001
PubMed
5) Boutin C, Rey F, Viallat JR : Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 108 : 754-758, 1995
PubMed
6) Hakkinen AM, Laasonen A, linnainmaa K et al : Radiosensitivity of mesothelioma cell lines. Acta Oncol 35 : 451-456, 1996
PubMed
7) Carmichael J, Degraff WG, Gamson J, et al : Radiation sensitivity of human lung cancer cell lines. Eur J Cancer Clin Oncol 25 : 527-534, 1989
PubMed
8) Maasilta P : Deterioration in lung function following hemithorax irradiation for pleural mesothelioma. Int J Radiat Oncol Biol Phys 20 : 433-438, 1991
PubMed
9) Hilaris BS, Nori D, Kwong E, et al : Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 10 : 325-331, 1984
PubMed
10) Lee TT, Everett DL, Shu HK, et al : Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 124 : 1183-1189, 2002
PubMed
11) Gupta V, Mychalczak B, Krug L, et al : Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 63 : 1045-1052, 2005
PubMed
12) Butchart EG, Ashcroft T, Barnsley WC, et al : Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax 31 : 15-24, 1976
PubMed
13) Yajnik S, Rosenzweig KE, Mychalczak B, et al : Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 56 : 1319-1326, 2003
PubMed
14) Sugarbaker DJ, Flores RM, Jaklitsch MT, et al : Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma : results in 183 patients. J Thorac Cardio vasc Surg 117 : 54-63 ; discussion 63-65, 1999
 
15) 澁谷景子, 成田雄一郎, 平岡眞寛 : 胸膜中皮腫の放射線治療. 画像診断 27 : 61-67, 2007
 
16) 澁谷景子, 成田雄一郎, 平岡眞寛 : アスベスト関連呼吸器疾患放射線治療. 臨床画像 23 : 49-56, 2007
 
17) Baldini EH, Recht A Strauss GM, et al : Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 63 : 334-338, 1997
PubMed
18) Allen AM, Czerminska M, Janne PA, et al : Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 65 : 640-645, 2006
PubMed
19) Wang S, Liao Z, Wei X, et al : Analysis of clinical and dosimetric factors associated With treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys 66 : 1399-1407, 2006
 
P.319 掲載の参考文献
1) Legha SS, Muggia FM : Pleural mesothelioma : Clinical features and therapeutic implications. Ann Intern Med 87 : 613-621, 1977
PubMed
2) Beauchamp HD, Kundra NK, Aranson R, et al : The role of closed pleural needle biopsy in the diagnosis of malignant mesothelioma of the pleura. Chest 102 : 1110-1112, 1992
PubMed
3) Dejmek A : Methods to improve the diagnostic accuracy of malignant mesothelioma. Respir Med 90 : 191-199, 1996
PubMed
4) Grossebner MW, Arifi AA, Goddard M, et al : Mesothelioma-VATS biopsy and lung mobilization improves diagnosis and palliation. Eur J Cardiothorac Surg 16 : 619-623, 1999
PubMed
5) Boutin C, Rey F : Thoracoscopy in pleural malignant mesothelioma : A prospective study of 188 consecutive patients. Cancer 72 : 389-393, 1993
PubMed
6) Shaw P, Aqarwal R : Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev (1) : CD002916, 2004
 
7) van Ruth S, Baas P, Haas RL, et al : Cytoreductive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy for stage I malignant pleural mesothelioma. Ann Surg Oncol 10 : 176-182, 2003
 
8) Friedberg JS, Mick R, Stevenson J, et al : A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma. Ann Thorac Surg 75 : 952-959, 2003
 
9) van Ruth S, Baas P, Zoetmulder FA : Surgical treatment of malignant pleural mesothelioma : a review. Chest 123 : 551-561, 2003
PubMed
10) International Mesothelioma Interest Group (IMIG) : A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 108 : 1122-1128, 1995
 
11) Sugarbaker DJ, Flores RM, Jaklitsch MT, et al : Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma : Resection in 183 patients. J Thorac Cardiovasc Surg 117 : 54-65, 1999
PubMed
12) Butchart EG, Ashcroft T, Barnsley WC, et al : Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura : Experience with 29 patients. Thorax 31 : 15-24, 1976
PubMed
13) Sugarbaker DJ, Jaklitsch MT, Bueno R, et al : Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 128 : 138-146, 2004
PubMed
14) Rusch VW, Venkatraman ES : Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 68 : 1799-1804, 1999
PubMed
15) McCormack PM, Nagasaki F, Hilaris BS, et al : Surgical treatment of pleural mesoithelioma. J Thorac Cardiovasc Surg 84 : 834-842, 1982
PubMed
P.328 掲載の参考文献
1) Berghmans T, Paesmans M, Lalami Y, et al : Activity of chemotherapy and immunotherapy on malignant mesothelioma : a systematic review of the literature With meta-analysis. Lung Cancer 38 : 111-121, 2002
PubMed
2) Lemer HJ, Schoenfeld DA, Martin A, et al : Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer 52 : 1981-1985, 1983
 
3) Vogelzang NJ, Taub RN, Shin DM : Phase In randomized trial of onconase (ONC) vs. doxorubicin (DOX) in patients (pts) with unresectable malignant mesothelioma (UMM) ; analysis of survival. Proc Am Soc Clin Oncol 19 : 577a (#2274), 2000
 
4) Mintzer DM, Kelsen D, Frimmer D, et al : Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. Cancer Trea t Rep 69 : 711-712, 1985
 
5) Zidar BL, Green S, Pierce HI, et al : A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma : a Southwest Oncology Group Study. Invest New Drugs 6 : 223-226, 1988
 
6) Mbidde EK, Harland SJ, Calvert AH, et al : Phase II trial of carboplatin (IM8) in treatment of patients with malignant mesothelioma. Cancer Chemoth er Pharmacol 18 : 284-285, 1986
 
7) Raghavan D, Gianoutsos P, Bishop J, et al : Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 8 : 151-154, 1990
PubMed
8) Vogelzang NJ, Goutsou M, Corson JM, et al : Carboplatin in malignant mesothelioma : a phase II study of the Cancer and Leukemia Group B. Cancer Chemother Pharmacol 27 : 239-242, 1990
 
9) Solheim OP ; Saeter G, Finnanger AM, et al : High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 65 : 956-960, 1992
PubMed
10) Bischoff HG, Manegold C, Knopp M, et al : Gemcitabine (Gemzar) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma. Proc Am Soc Clin Oncol 17 ; 464a, 1998
 
11) van Meerbeeck JP, Baas P, Debruyne C, et al : A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer 85 : 2577-2582, 1999
PubMed
12) Kindler HL, Millard F, Herndon JE, 2nd, et al : Gemcitabine for malignant mesothelioma : A phase II trial by the Cancer and Leukemia Group B. Lung Cancer 31 : 311-317, 2001
 
13) Scagliotti GV, Shin DM, Kindler HL, et al : Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 21 : 1556-1561, 2003
PubMed
14) Baas P, Ardizzoni A, Grossi F, et al : The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma : an EORTC phase II study (08992). Eur J Cancer 39 : 353-357, 2003
PubMed
15) Steele Jp, Shamash J, Evans MT, et al : Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 18 : 3912-3917, 2000
PubMed
16) Byrne MJ, Davidson JA, Musk AW, et al : Cisplatin and gemcitabine treatment for malignant mesothelioma : a phase II study, J Clin Oncol 17 : 25-30, 1999
PubMed
17) Nowak AK, Byrne MJ, Williamson R, et al : A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 87 : 491-496, 2002
 
18) van Haarst JM, Baas P, Manegold C, et al : Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 86 : 342-345, 2002
PubMed
19) Castagneto B, Zai S, Dongiovanni D, et al : Cisplatin and gemcitabine in malignant pleural mesothelioma : a phase II study. Am J Clin Oncol 28 : 223-226, 2005
PubMed
20) Aversa SM, Favaretto AG : Carboplatin and gemcitabine chemotherapy for malignant pleural mesothelioma : a phase II study of the GSTPV. Clin Lung Cancer 1 : 73-75, 1999
PubMed
21) Favaretto AG, Aversa SM, Paccagnella A, et al : Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma : a multicentric phase II study. Cancer 97 : 2791-2797, 2003
PubMed
22) Nakano T, Chahinian AP, Shinjo M, et al : Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma : a pilot phase II clinical trial and pharmacokinetic profile. Cancer 85 : 2375-2384, 1999
PubMed
23) Thodtmann R, Depenbrock H, Dumez H, et al : Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 17 : 3009-3016, 1999
PubMed
24) Hughes A, Calvert P, Azzabi A, et al : Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 20 : 3533-3544, 2002
PubMed
25) Ceresoli GL, Zucali PA, Favaretto AG, et al : Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 24 : 1443-1448, 2006
PubMed
26) Janne PA, Obasaju C, Simon G, et al : A phase II clinical trial of pemetrexed plus gemcitabine as front-line chemotherapy for patients with malignant pleural mesothelioma (MPM). Proc Am Soc Clin Oncol 22 : 14S (#7053), 2004
 
27) Fizazi K, Doubre H, Le Chevalier T, et al : Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma : results of a phase II study. J Clin Oncol 21 : 349-354, 2003
PubMed
28) Middleton GW, Smith IE, O'Brien ME, et al : Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 9 : 269-273, 1998
PubMed
29) Andreopoulou E, Ross PJ, O'Brien ME, et al : The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma. Ann Oncol 15 : 1406-1412, 2004
PubMed
30) Vogelzang NJ, Rusthoven JJ, Symanowski J, et al : Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 : 2636-2644, 2003
PubMed
31) van Meerbeeck JP, Gaafar R, Manegold C, et al : Randomized phase In study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma : an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23 : 6881-6889, 2005
 
32) Muers MF, Rudd RM, O'Brien ME, et al : BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma : ISRCTN 54469112. Thorax 59 : 144-148, 2004
PubMed
33) Niyikiza C, Baker SD, Seitz DE, et al : Homocysteine and methylmalonic acid : markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1 : 545-552, 2002
PubMed
34) Konig JE, Tolnay E, Wiethege T, et al : Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma. Virchows Arch 435 : 8-12, 1999
PubMed
35) Kumar-Singh S, Vermeulen PB, Weyler J, et al : Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma. J Pathol 182 : 211-216, 1997
PubMed
36) Ohta Y, Shridhar V, Bright RK, et al : VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 81 : 54-61, 1999
PubMed
37) Kindler HL, Karrison T, Lu C, et al : A multicenter, double-blind, placebo-controlled randomized phase n trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo in patients (pts) with malignant mesothelioma (MM). Proc Am Soc Clin Oncol 23 : 16S (#7019), 2005
 
38) Kindler HL, Vogelzang NJ, Chien K, et al : SU5416 in malignant mesothelioma : aUniversity of Chicago Phase II Consortium Study. Proc Am Soc Clin Oncol 20 : (# 1359), 2001
 
39) Baas P, Boogerd W, Dalesio O, et al : Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 48 : 291-296, 2005
PubMed
40) Mathy A, Baas P, Dalesio O, et al : Limited efficacy of imatinib mesylate in malignant mesothelioma : a phase II trial. Lung Cancer 50 : 83-86, 2005
PubMed
41) Porta C, Mutti L, Tassi G : Negative results of an Italian Group for Mesothelioma (G. I. Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemoth er Pharmacol, 2006
 
42) Govindan R, Kratzke RA, Herndon JE, 2nd, et al : Gefitinib in patients with malignant mesothelioma : a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 11 : 2300-2304, 2005
 
43) Garland L, Rankin C, Scott K, et al : Molecular correlates of the EGFR signaling pathway in association with SWOG S0218 : A phase II study of oral EGFR tyrosine kinase inhibitor OSI-774 (NSC-718781) in patients with malignant pleural mesothelioma (MPM). Proc Am Soc Clin Oncol 22 : 14S (#3007), 2004
 
44) Buchdunger E, Cioffi CL, Law N, et al : Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295 : 139-145, 2000
 
45) Kelly WK, O'Connor OA, Krug LM, et al : Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23 : 3923-3931, 2005
 
46) Sun X, Gulyas M, Hjerpe A, et al : Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells. Cancer Lett 232 : 161-169, 2006
PubMed
47) Manegold C, Symanowski J, Gatzemeier U, et al : Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 16 : 923-927, 2005
PubMed
48) Giaccone G, O'Brien ME, Byme MJ, et al : Phase II trial of ZD0473 as second-line therapy in mesothelioma. Eur J Cancer 38 Suppl 8 : S19-24, 2002
 
49) Mikulski SM, Costanzi JJ, Vogelzang NJ, et al : Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 20 : 274-281, 2002
PubMed
P.336 掲載の参考文献
1) Loehrer PJ, Chen M, Kim K, et al : Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma : an intergroup tria1. J Clin Oncol 15 : 3093-3099, 1997
 
2) Kunitoh H, Tamura T, Fukuda H, et al : Dose intensive chemotherapy in advanced thymoma : Initial report of Japan Clinical Oncology Group trials (JCOG 9605 and 9606). Proc Am Soc Clin Oncol 24 : 7080, 2006
 
3) Kim ES, Putnam JB, Komaki R, et al : Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas : final report. Lung Cancer 44 : 369-379, 2004
PubMed
4) Fomasiero A, Daniele O, Ghiotto C, et al : Chemotherapy for invasive thymoma. A 13-year experience. Cancer 68 : 30-33, 1991
PubMed
5) Highley MS, Underhill CR, Parnis FX, et al : Treatment of invasive thymoma with single-agent ifosfamide. J Clin Oncol 17 : 2737-2744, 1999
PubMed
6) Bonomi PD, Finkelstein D, Aisner S, et al : EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma. Am J Clin Oncol 16 : 342-345, 1993
PubMed
7) Loehrer PJ, Kim K, Aisner SC, et al : Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma : final results of an intergroup trial. The Eastem Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 12 : 1164-1168, 1994
PubMed
8) Loehrer pJ, Jiroutek M, Aisner S, et al : Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma : an intergroup trial. Cancer 91 : 2010-2015, 2001
PubMed
9) Giaccone G, Ardizzoni A, Kirkpatrick A, et al : Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 14 : 814-820, 1996
PubMed
10) Umemura S, Segawa Y, Fujiwara K, et al : A case of recurrent metastatic thymoma showing a marked response to paclitaxel monotherapy. Jpn J Clin Oncol 32 : 262-265, 2002
PubMed
11) Gidron A, Quadrini M, Dimov N, et al : Malignant thymoma associated with fatal myocarditis and polymyositis in a 32-year-old woman with a history of hairy cell leukemia. Am J Clin Oncol 29 : 213-214, 2006
 
12) Kurup A, Bums M, Dropcho, et al : Phase II study of gefitinib treatment in advanced thymic malignancies. Proc Am Soc Clin Oncol 23 : 7068, 2005
 
13) Loehrer PJ, Yiannoutsos CT, Dropcho S, et al : A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. Proc Am Soc Clin Oncol 24 : 7079, 2006
 
14) Kobayashi Y, Fujii Y, Yano M, et al : Preoperative Steroid Pulse Therapy for Invasive Thymoma. Clinical Experience and Mechanism of Action. CANCER 106 : 1901-1907, 2006
PubMed
15) Palmieri G, Montella L, Martignetti A, et al : Somatostatin Analogs and Prednisone in Advanced Refractory Thymic Tumors.oA VCER 94 : 1414-1420, 2002
 
16) Loehrer PJ, Wang W, Johnson DH, et al : Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma : an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol 22 : 293-299, 2004
PubMed
P.346 掲載の参考文献
1) Im J, Webb WR, Rosen A : Costal pleura : appearances at high-resolution CT. Radiology 171 : 125-131, 1989
PubMed
2) Pennes DR, Glazer GM, Wimbish KJ : Chest wall invasion by lung cancer : limitations of CT evaluation. AIR Am J Roentgenol 144 : 507-511, 1985
 
3) Garcia VF, Seyfer AE, Graeber GM : Reconstruction of congenital chest-wall deformities. Surg Clin North Am 69 : 1103-1118, 1989
PubMed
4) Swischuk LE, Stansberry SD : Radiographic manifestations of anomalies of the chest wall. Radiol Clin North Am 29 : 271-277, 1991
PubMed
5) Fisher MS : Eve's rib (letter). Radiology 140 : 841, 1981
 
6) Fallet GH, Lagier R, Gerster JC, et al : Sternocostoclavicular hyperostosis (SCCHO) with palmoplantar pustulosis (PPP). Clin Exp Rheumatol 5 : 135-141, 1987
PubMed
7) Franquet T, Gimenez A, Alegret X, et al : Imaging findings of stemal abnormalities. Eur Radiol 7 : 492-497, 1997
 
8) Stein HL : Roentgen diagnosis of congenital absence of pectoralis muscles. Radiology 83 : 63-66, 1964
PubMed
9) Wright AR, Milner RH, Bainbridge LC, et al : MR and CT in the assessment of Poland syndrome. J Comput Assist Tomogr 16 : 442-447, 1992
PubMed
10) Felson B : Chest rentgenology ; the mediastinum. WB Saunders, Philadelphia, 1973
 
11) Ellis R : Incomplete border sign of extrapleural masses. JAMA 237 : 2748, 1977
PubMed
12) Renner RR, Markarian B, Pemice NJ, et al : The apical cap. Radiology 110 : 569-573, 1974
 
13) Hamlin DJ, Burgener FA : CT, including sagittal and coronal reconstruction, in the evaluation of pancoast tumors. J Comput Tomogr 6 : 43-50, 1982
PubMed
14) Schaefer PS, Burton BS : Radiographic evaluation of chest-wall lesions. Surg Clin North Am 69 : 911-945, 1989
PubMed
15) Schwarz J, Baum GL : Actinomycosis. Semin Roentgenol 5 : 58-63, 1970
 
16) Webb WR, Sagel SS : Actinomycosis involving the chest wall : CT findings. AJR Am J Roentgenol 139 : 1007-1009, 1982
PubMed
17) Bhatt GM, Austin HM : CT demonstration of empyema necessitates. J Comput Assist Tomogr 9 : 1108-1109, 1985
 
18) Glicklich M, Mendelson DS, Gendal ES, et al : Tuberculous empyema necessitates. Computed tomography findings. Clin Imaging 14 : 23-25, 1990
 
19) Teixeira JP : Concerning the Pancoast tumor : what is the superior pulmonary sulcus? Ann Thorac Surg 35 : 577-578, 1983
PubMed
20) Ginsberg RJ, Martini N, Zaman M, et al : Influence of surgical resection and brachytherapy in the management of superior sulcus tumor. Ann 7horac Surg 57 : 1440-1445, 1994
PubMed
21) Arcasoy SM, Jett JR : Superior pulmonary sulcus tumors and Pancoastls syndrome. N Engl J Med 337 : 1370-1376, 1997
PubMed
22) O'Connell RS, McLoud TC, Wilkins EW : Superior sulcus tumor : radiographic diagnosis and workup. AJR Am J Roentgenol 140 : 25-30, 1983
PubMed
23) Cavanaugh DG, Barry MJ, Knight JA, et al : Diagnosis of superior sulcus tumors : afurther use of the thoracoscope. Mil Med 158 : 577-578, 1993
 
24) Weinreb JC, Naidich DP : Thoracic magnetic resonance imaging. Clin Chest Med 12 : 33-54, 1991
PubMed
25) Laissy Jp, Soyer P, Sekkal SR, et al : Assessment of vascular involvement with magnetic resonance angiography (MRA) in Pancoast syndrome. Magn Reson Imaging 13 : 523-530, 1995
PubMed
26) Murphey MD, Gross TM, Rosenthal HG : Musculoskelet al malignant fibrous histiocytoma : radiologic-pathologic correlation. Radio Graphics 14 : 807-828, 1994
 
27) Almberger M, Iannicelli E, Matrunola M, et al : Integrated diagnostic imaging of primary thoracic rhabdomyosarcoma. Eur Radiol 11 : 506-508, 2001
PubMed
28) Fink U, Kurtz DW, Cazenave L, et al : Malignant thoracopulmonary small-cell ("Askin") tumor. AJR Am J Roentgenol 145 : 517-520, 1985
 
29) O'Keeffe F, Lorigan JG, Wallace S : Radiological features of extraskelet al Ewing sarcoma. Br J Radiol 63 : 456-460, 1990
 
30) Tateishi U, Gladish GW, Kusumoto M, et al : Chest Wall Tumors : Radiologic Findings and Pathologic Correlation : Part 1. Benign Tumors Radio Graphics 23 : 1477-1490, 2003
 
31) Kuhlman JE, Bouchardy L, Fishman EK, et al : CT and MR imaging evaluation of chest wall disorders. Radio Graphics 14 : 571-595, 1994
 
32) Anderson BO, Burt ME : Chest wall neoplasms and their management. Ann Thorac Surg 58 : 1774-1781, 1994
PubMed
33) Zhang Y, Nishimura H, Kato S, et al : MRI of ganglioneuroma : histologic correlation study. J Compput Assist Tomogr 25 : 617-623, 2001
PubMed
34) Buetow PC, Kransdorf MJ, Moser RP, et al : Radiologic appearance of intramuscular hemangioma with emphasis on MR imaging. AJR Am J Roentgenol 154 : 563-567, 1990
PubMed
35) Naylor MF, Nascimento AG, Sherrick AD, et al : Elastofibroma dorsi : radiologic findings in 12 patients. AJR Am J Roentgenol 167 : 683-687, 1996
PubMed
36) Sargent EN, Gordonson J, Jacobson G, et al : Bilateral pleural thickening : a manifestation of asbestos dust exposure. AJR Am J Roentgenol 131 : 579-585, 1978
PubMed
37) Stephens M, Gibbs AR, Pooley FD, et al : Asbestos induced diffuse pleural fibrosis : pathology and mineralogy. Thorax 42 : 583-588, 1987
PubMed
38) Bonomo L, Feragalli B, Sacco R, et al : Malignant pleural disease. Eur J Radiol 34 : 98-118, 2000
PubMed
39) Brenner J, Sordillo PP, Magill GB, et al : Malignant mesothelioma of the pleura : review of 123 patients. Cancer 49 : 2431-2435, 1982
PubMed
40) Grant DC, Seltzer SE, Antman KH, et al : Computed tomography of malignant pleural mesothelioma. J Comput Assist Tomogr 7 : 626-632, 1983
PubMed
41) Alexander E, Clark RA, Colley DP, et al : CT of mahgnant pleural mesothehoma. AJR Am J Roentgenol 137 : 287-291, 1983
 
42) Dynes MC, White EM, Fry WA, et al : Imaging manifestations of pleural tumors. Radio Graphics 12 : 1191-1201, 1992
 
43) Briselli M, Mark EJ, Dickersin GR : Solitary fibrous tumors of the pleura : eight new cases and review of 360 cases in the literature. Cancer 47 : 2678-2689, 1981
PubMed
44) Magdeleinat P, Alifano M, Petino A et al : Solitary fibrous tumors of the pleura : clinical characteristics, surgical treatment and outcome. Eur J Cardio th orac Surg 21 : 1087-1093, 2002
 
45) Ferretti GR, Chiles C, Choplin RH, et al : Localized benign fibrous tumors of the pleura. AJR Am J Roentgenol 169 : 683-686, 1997
PubMed
46) Lee KS, Im J-G, Choe KO, et al : CT findings in benign fibrous mesothelioma of the pleura : pathologic correlation in nine patients. AJR Am J Roentgen 01 158 : 983-986, 1992
 
47) Ferretti GR, Chiles C, Cox JE, et al : Localized benign fibrous tumors of the pleura : MR appearance. J Comput Assist Tomogr 21 : 115-120, 1997
PubMed
48) Iuchi K, Ichimiya A, Akashi A, et al : Non-Hodgkin's lymphoma of the pleural cavity developing from long-standing pyothorax. Cancer 60 : 1771-1775, 1987
PubMed
49) Minami M, Kawauchi N, Yoshikawa K, et al : Malignancy associated with chronic empyema : radiologic assessment. Radiology 178 : 417-423, 1991
PubMed
50) Donovan PB, Eng P : Pleural changes in malignant pleural effusions : appearance on computed tomography. Cleve Clin J Med 61 : 127-131, 1994
 
51) Murayama S, Murakami J, Yoshimitsu K, et al : CT diagnosis of pleural dissemination without pleural effusion in primary lung cancer. Radiat Med 14 : 117-119, 1996
PubMed
52) Zerhouni EA Scott WW Jr, Baker RR, et al : Invasivethymomas : diagnosisand evaluationbycomputedtomography. J Comput Assist Tomogr 6 : 92-100, 1982
 
53) Normand JP, Rioux M, Dumont M, et al : Thoracic splenosis after blunt trauma : frequency and imaging findings. AJR Am J Roentgenol 161 : 739-741, 1993
PubMed
54) Arzoumanian A, Rosenthall L : Splenosis. Clin Nucl Med 20 : 730, 1995
PubMed
P.355 掲載の参考文献
1) Rosai J, Sobin LH : Histological typing of tumours of the thymus. International histological classification of tumours, 2nd edition, Springer, New York, Berlin, 1999
 
2) World Health Organization Classification of Tumors. Pathology and genetics of tumors of the lung, pleura, thymus and heart. International Agency for Research on Cancer (LARC) Press, Lyon Franc, 2004
 
3) Bernatz PE, Harrison EG, Clagett OT : Thymoma : a clinicopathologic study. J Thorac Cardiovasc Surg 42 : 424-444, 1961
PubMed
4) Muller-Hermelink HK, Marino M, Palestro G, et al : Immunohistological evidences of cortical and medullary differentiation in thymoma. Virchows Arch Pathol Anat 408 : 143-161, 1985
PubMed
5) Muller-Hermelink HK, Marino M, Palestro G : Pathology of thymic epithelial tumors. Curr Top Pathol 75 : 207-268, 1986
PubMed
6) Kirchner T, Schalke B, Buchwald J, et al : Well-differentiated thymic carcinoma. An organotypical low-grade carcinoma with relationship to cortical thymoma. Am j Surg Pathol 16 : 1153-1169, 1992
PubMed
7) Masaoka A, Monden Y, Nakahara K, et al : Follow-up study of thymomas with special reference to their clinical stages. Cancer 48 : 2485-2492, 1981
PubMed
8) Okumura M, Miyoshi S, Fujii Y, et al : Clinical and functional significance of WHO classification on human thymic epithelial neoplasms. A study of 146 consecutive tumors. Am J Surg Pathol 25 : 103-110, 2001
PubMed
9) Okumura M, Ohta M, Tateyama H, et al : The World Health Organization histologic classification system reflects the oncologic behavior of thymoma. A clinical study of 273 patients. Cancer 94 : 624-632, 2002
PubMed
10) Zettl A, Strobel P, Wagner K, et al : Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol 157 : 257-266, 2000
PubMed
11) Inoue M, Starostik P, Zettl A, et al : Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas. Cancer Res 63 : 3708-3715, 2003
PubMed
12) Okumura M, Miyoshi S, Takeuchi Y, et al : Results of surgical treatment of thymomas With special reference to the involved organs. J Thorac Cardiovasc Surg 117 : 605-613, 1999
 
13) Kondo K, Monden Y : Therapy for Thymic epithelial tumors : aclinical study of 1320 patients from Japan. Ann Thorac Surg 76 : 878-884, 2003
 
14) Kondo K, Monden Y. Thymoma and myasthenia gravis : a clinical study of 1089 patients from Japan. Ann Thorac Surg 79 : 219-224, 2005
 
15) Tomiyama N, Johkoh T, Mihara N, et al : Using the World Health Organization classification of thymic epithelial neoplasms to describe CT findings. Am J Roentgenol 179 : 881-886, 2002
 
16) Murakawa T, Nakajima J, Kohno T, et al : Results of surgical treatment for thymoma. 43 years of experience. Jpn J Thorac Cardiovasc Surg 48 : 89-95, 2000
PubMed
17) Okumura M, Shiono H, Inoue M, et al : Outcome of surgical treatment for recurrent thymic epithelial tumors with reference to World Health Organization histologic classification system. J Surg Oncol 95 : 40-44, 2007
PubMed
P.362 掲載の参考文献
1) Bokemeyer C, Nichols CR, Droz JP, et al : Extragonadal germ cell tumors of the mediastinum and retroperitoneum : results from an international analysis. J Clin Oncol 20 : 1864-1873, 2002
PubMed
2) Horwich A, Shipley J, Huddart R : Testicular germ-cell cancer. Lancet 367 : 754-765, 2006
PubMed
3) International Germ Cell Cancer Collaborative Group : International germ cell consensus classification : A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15 : 594-603, 1997
 
4) Schmoll HJ, Souchon R, Krege S, et al : European consensus on diagnosis and treatment of germ celi cancer : a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15 : 1377-1399, 2004
 
5) Bush SE, Matinez A, Bagshaw MA : Primary mediastinal seminoma. Cancer 48 : 1877-1882, 1981
 
6) Puc HS, Heelan R, Mazumdar M, et al : Management of residual mass in advanced seminoma : results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 14 : 454-460, 1996
 
7) Santis MD, Becherer A, Bokemeyer C, et al : 2-18fluoro-deoxy-D-glucose positron emission tomography Is a Reliable Predictor for Viable tumor in postchemotherapy seminoma : an update of the prospective multicentric SEMPET Trial. J Clin Oncol 22 : 1034-1039, 2004
 
8) Mazumdar M, Bajorin DF, Bacik J, et al : Predicting outcome to chemotherapy in patients with germ cell tumors : The value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol 19 : 2534-2541, 2001
 
9) Fizazi K, Tjulandin S, Salvioni R, et al : Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors : prognostic factors and role of postsurgery chemotherapy-results from an Intemational Study Group. J Clin Oncol 19 : 2647-2657, 2001
 
10) Kollmannsberger C, Dohmen BM, Pfannenberg A, et al : Prospective comparison of [18F] fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma. Cancer 94 : 2353-2362, 2002
PubMed
11) Vuky J, Bains M, Bacik J, et al : Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum. J Clin Oncol 19 : 682-688, 2001
 
12) Schneider BP, Kesler KA, Brooks JA, et al : Outcome of patients with residual genn cell or non-germ cell malignancy after resection of primary mediastinal nonseminomatous germ cell cancer. J Clin Oncol 22 : 1195-1200, 2004
PubMed
13) Williams SD, Birch R, Einhom LH, et al : Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316 : 1435-1440, 1987
PubMed
14) Hinton S, Catalano PJ, Einhorn LH, et al : Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors. Cancer 97 : 1869-1875, 2003
PubMed
15) Collette L, Sylvester RJ, Stenning SP, et al : Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. J Natl Cancer Inst 91 : 839-846, 1999
PubMed
16) Samson MK, Rivkin SE, Jones SE, et al : Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. A Southwest Oncology Group Study. Cancer 53 : 1029-1035, 1984
 
17) Nichols CR, Williams SD, Loehrer PJ, et al : Randomized study of cisplatin dose intensity in poor-risk germ cell tumors : A Southeastem Cancer Study Group and Southwest Oncology Group Protocol. J Clin Oncol 9 : 1163-1172, 1991
 
18) Toner GC, Stockler MR, Boyer MJ, et al : Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours : a randomised trial. Lancet 357 : 739-745, 2001
PubMed
19) Culine S, Kerbrat P, Bouzy J, et al : The optimal chemotherapy regimen for good-risk metastatic non seminomatous germ cell tumors (MNSGCT) is 3 cycles of bleomycin, etoposide and cisplatin : Mature results of a randomized trial. Proc Am Soc Clin Oncol 22 : #1536, 2003 (abstr)
 
20) Wit RD, Stoter G, Kaye SB, et al : Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma : A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 15 : 1837-1843, 1997
 
21) Harstrick A, Schmoll HJ, Wilke H, et al : Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J Clin Oncol 9 : 1549-1555, 1991
PubMed
22) Pizzocaro G, Salvioni R, Piva L, et al : Modified cisplatin, etoposide (or vinblastine) and ifosfamide salvage therapy for male germ-cell tumors : long-term results. Ann Oncol 3 : 211-216, 1992
 
23) Farhat F, Culine S, Theodore C, et al : Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for reffactory or relapsing germ cell tumor patients : the Institute Gustave Roussy experience. Cancer 77 : 1193-1197, 1996
 
24) McCafiiley JA, Mazumdar M, Bajorin DF, et al : Ifosfamide-and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors : response and survival. J Clin Oncol 15 : 2559-2563, 1997
 
25) Loehrer PJ, Gonin R, Nichols CR, et al : Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16 : 2500-2504, 1998
PubMed
26) Kondagunta GV, Bacik J, Donadio A, et al : Combination of paclitacel, ifosfamide, and cisplatin is an effective secondline therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 23 : 6549-6555, 2005
 
27) Pico JL, Rosti G, Kramar A, et al : A randomized trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 16 : 1152-1159, 2005
PubMed
28) Miller JC, Einhom LH : Phase n study of daily oral etoposide in refractory germ cell tumors. Semin Oncol 17 : 36-39, 1990
 
29) Hinton S, Catalano P, Einhorn LH, et al : Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897) : a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 20 : 1859-1863, 2002
 
30) Kokkmannsberger C, Beyer J, Liersch R, et al : Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer : a study of the Geman Testicular Cancer Study Group. J Clin Oncol 22 : 108-114, 2004
 

書評

最近チェックした商品履歴

Loading...